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Introduction:  
 
Cystic Fibrosis has always been a point of interest in our paediatric pulmonology department. 
Since the establishment of  Cystic Fibrosis (CF) centres in Belgium in 1999 the care for CF 
patients became better organized. Because the staff was expanded by paramedical co-workers, 
such as CF nurses, physiotherapists, nutritionists  and  psychologists, it also became easier to 
set up both inter-centre and multi-centre studies. 
Although we are convinced that peer contacts are psychologically beneficial for patients 
dealing with CF, we wanted to ensure that our patients did not experience more harm than 
benefit from these contacts, by patient-to-patient transmission of bacteria. 
Pseudomonas aeruginosa is known to be the most important pathogen in CF, and is 
associated with increased morbidity and reduced life expectancy.  
Therefore we set up a first study in the CF rehabilitation centre “Zeepreventorium De Haan” , 
to compare the genotypes of the P. aeruginosa isolates carried by chronically infected 
patients, during several months (publication 1, p. 73).  
Because of the ongoing debate of the necessity of cohorting patients, chronically infected by 
P. aeruginosa, we set up a national data bank of P. aeruginosa genotypes from these CF 
patients, in collaboration with all 7 Belgian CF centres (publication 2, p. 83). 
During the De Haan study we noticed that many of the patients, chronically infected by P. 
aeruginosa also seemed to be infected or even co-colonized with Achromobacter 
xylosoxidans (A. xylosoxidans). Since there is little knowledge about the occurrence and 
transmissibility of this organism within CF patients, we set up a study to compare genotypes 
of A. xylosoxidans in the same population in the Zeepreventorium (publication 3, p. 113).  
The clinical significance of this micro-organism is unclear and until now, there is limited 
evidence for necessity of treatment. 
Therefore we set up a retrospective case control study  to examine the clinical impact of 
chronic A. xylosoxidans infection (publication 4, p. 120). 
 
 Chapter I. Etiology of Cystic Fibrosis (CF): 
 
Cystic Fibrosis is a condition caused by a genetic defect that leads to a variety of 
abnormalities in the CF transmembrane conductance regulator (CFTR). 
The CFTR gene is located on the long arm of chromosome 7.  The CF gene is large, spans 250 
kb, and is composed of 27 exons. As shown in Figure 1 the gene is transcribed into a 6.5-kb 
messenger RNA that encodes a 1,480 amino acid protein. Since identification of the gene, 
over 1000 disease-associated mutations in the CF gene have been reported to the CF Genetic 
Analysis Consortium database (www.genet.sickkids.on.ca/cftr/).  
 
Since it is an autosomal recessive disease, two mutant CFTR genes are necessary to produce a 
Cystic Fibrosis Phenotype (CFP). This phenotype is characterized by a very wide spectrum, 
spanning severely ill neonates to newborns with subclinical disease. 
 
 
Figure 1. The cystic fibrosis (CF) transmembrane conductance regulator (CFTR) gene and its encoded 
polypeptide. [1] 
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 The human CFTR gene is located on the long arm of chromosome 7. The mature protein after 
proper folding, glycosylation, and insertion into the cell membrane is shown at the bottom of 
fig.1. The CFTR protein is a member of the ATP-binding cassette family of transporters. It 
contains two nucleotide-binding domains that bind and hydrolyze ATP, two dual sets of 
membrane-spanning segments that form the channel, and a central regulatory (R) domain. The 
R domain, unique to CFTR, is highly charged with numerous phosphorylation sites for 
protein kinases A or C [1]. 
 The mutations in the CF gene can disrupt CFTR function in different ways, ranging from 
complete loss of protein to surface expression with poor chloride conductance. The five major 
mechanisms by which CFTR function is altered are summarized in Figure 2. 
 
 Class I mutations produce premature transcription termination signals resulting in unstable, 
truncated, or no protein expression. 
Class II mutations, usually mis-sense mutations including F508, cause the protein to misfold 
leading to premature degradation and failure to reach the apical cell membrane. 
 Class III mutations, primarily located in the two nuclear-binding domains, result in decreased 
chloride channel activity due to abnormal adenosine triphosphate (ATP) gating.  
Class IV mutations are primarily located in the membrane spanning domains that form the 
chloride channel and demonstrate reduced chloride conductance. 
 Class V mutations result in reduced amounts of functional protein (rather than no protein 
production seen in Class I) due to abnormal or alternative splicing.  
It is important to recognize that specific mutations may have characteristics of more than one 
class. Thus, these five mechanisms of CFTR dysfunction are intended to provide a framework 
for understanding the molecular basis of epithelial cell abnormalities in CF, help predict 
16
 observed genotype–phenotype correlations, and develop treatment approaches directed to 
specific classes of mutations. 
 
 
 
Figure 2. Class I-V mutations of CFTR [1] 
 
CFTR: function and regulation:  
After identification of the CF gene in 1989, the 1990s was a decade associated with rapid 
expansion of knowledge regarding the structure and function of the CF gene product, CF 
transmembrane conductance regulator (CFTR) protein. 
 
CFTR is an ATP-dependent Cl- channel that mediates cAMP-mediated Cl- secretion by 
epithelia, predominantly those in the pancreas, airways and intestine. 
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 Besides its predominant function as a Cl- channel it has additional functions:  
- There is good evidence  that CFTR also regulates amiloride-sensitive epithelial 
sodium channels [2, 3]. 
- Possibly the CFTR channel conducts ATP to the extracellular compartment, which 
serves as an autocrine activator of CFTR itself [4], of the outwardly rectifying Cl-
channels [5, 6], and possibly of other transporters in the apical membrane [7].  
- According to Bradbury [8] CFTR plays a role in endocytosis and exocytosis. 
- The CFTR protein may also function as a chloride channel in intracellular 
compartments [9]. 
 
A recent review by Mehta [10] focuses on functions of CFTR that do not directly relate to a 
disease mechanism based on channelopathy. The key concept is that newly synthesized CFTR 
has to enter lipid vesicles which bud from the endoplasmic reticulum. This is abnormally low 
in ΔF508 CFTR. Normal wild type vesicular CFTR continuously cycles between exposure at 
the apical membrane and retrieval in subapical recycling compartment, but this retrieval is 
abnormally fast in ΔF508 CFTR. The review discusses the relationship between this process 
and the topic of fat metabolism and the possible links between abnormal fatty acid turnover 
and inflammatory cascades that are abnormal in cystic fibrosis. AMP-activated kinase, which 
is bound near the C terminus of the CFTR protein, could possibly integrate some of the 
abnormalities in lipid metabolism that result from mislocalization of CFTR in clinical disease.    
 
Genotype-phenotype prediction is an important area of CF research. In brief, it has been 
possible to predict the severity of the CF organ-level phenotype from the genotype with high 
fidelity with respect to the sweat ducts, the pancreas, and the reproductive system. In contrast, 
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 it is still difficult to identify correlations between genotype and phenotype, i.e. severity, of 
lung disease. For instance, patients who are homozygous for the ΔF508 mutation exhibit a 
wide spectrum in the rate of development and severity of lung disease.  
The failure to generate genotype-phenotype predictions in the lung has led to the notion that 
both environmental-lung interactions and the genetic background of the host contribute 
substantially to the severity of CF lung disease. Therefore, a search has been initiated for 
"modifier genes", i.e. genes that modify the effect of CF mutations on lung dysfunction. At 
present, a number of modifier genes have been identified, based on "candidate selection". 
Thus far, these genes appear to include those that regulate aspects of innate lung defence and 
inflammatory cascades [11] (see Chapter III).  
19
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 Chapter II. Clinical epidemiology of CF 
 
Epidemiology may be defined as the study of the distribution and of the determinants of 
disease frequency in human populations. 
Clinical epidemiology applies epidemiological principles to a clinical population, i.e. to a 
population already known to have a particular disease. 
 
a. Diagnosis: 
 
Diagnosis of cystic fibrosis is  mostly made on clinical grounds (or on neonatal screening, in 
regions where applied). The gold standard for CF diagnosis is the sweat test, which uses 
pilocarpine iontophoresis to produce sweat for chloride analysis [12]. According to the US CF 
Foundation Patient Data Registry Annual Data Report of 1996, 98% of patients have sweat 
sodium or chloride above 61 meq/L, with a mean sweat chloride of 101.7 meq/l (standard 
deviation 18.91 meq/l). Seventy percent of the US patients are diagnosed before the age of 1 
year, and 90% before their 8th birthday [13]. According to the Belgian CF registry of 2003, 
68% of the patients is diagnosed before the age of 1 year, 73% before 2 years and 90% before 
their 12th anniversary [14]. 
 
Late diagnosis is associated with milder disease (better lung function and nutritional status), 
and lower prevalence of colonization with P. aeruginosa . 
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 b. Life expectancy:  
The median survival age increased significantly during the 2 last decades (Figure 3). 
 
Figure 3. Median survival age in cystic fibrosis, 1985–2001. Data from the U.S. Cystic Fibrosis Foundation 
Patient Registry showing the age of expected death for 50% of the current Registry population, given the ages of 
the patients in the Registry and the mortality distribution of deaths for that specific year. The 95% confidence 
intervals for the survival estimate are denoted by the vertical bars. The median estimated survival is 33.4 years 
for 2001. 
c. Clinical presentation:  
 
Acute or persistent respiratory symptoms are the most common clinical manifestation (51%), 
followed by failure to thrive or malnutrition, steatorrhoe or abnormal stools (43%) and 
meconium ileus or intestinal obstruction (distal intestinal obstruction syndrome: DIOS) 
(19%). 
Congenital bilateral absence of the vas deferens (CBAVD) is a clinical syndrome in which 
there is a high prevalence of CFTR mutations (14.5% being homozygous for CFTR 
mutations, 48.1% being heterozygous and 37.5% having no CFTR mutations). Homozygous 
CBAVD patients frequently have abnormal sweat test, but only a few have clinical symptoms, 
compatible with CF. 
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 Respiratory symptoms: 
Due to progressive lung damage there is a gradual decline in lung function parameters. The 
mechanisms responsible for this lung damage are described below (see Chapter III). 
The organism most frequently reported in CF sputum is P. aeruginosa. The prevalence of P. 
aeruginosa colonization varies between countries and between treatment centres in countries. 
For example, the isolation frequency for P. aeruginosa in Canada was 48% in 1995, but 
varied between treatment centres from 25% to 52%. The reported prevalence in New Zeeland 
is 62%, it is 62% in French adults and 69% in Ireland [12].  
In Belgium the total number of CF patients, registered in the Belgian registry in 2003, was 
843, of whom 750 are followed at the 7 CF centres and 280 are considered as colonised by P. 
aeruginosa (37%) [14].  
 
 
The pathophysiology of  infection with P. aeruginosa is described below. Other organisms, 
cultured from the respiratory tract of Belgian CF patients are represented in Table 1. 
Results          n        % 
Sterile culture 17 2.2 
Normal microflora 146 19.1 
Pseudomonas aeruginosa 216 28.2 
Mucoïd Pseudomonas aeruginosa 116 15.2 
Other Pseudomonas species 5 0.7 
Burkholderia cepacia 5 0.7 
Stenotrophomonas maltophilia 32 4.2 
Staphylococcus aureus 338 44.2 
Haemophilus influenzae 104 13.6 
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 Candida spp. 149 19.5 
Aspergillus spp. 118 15.4 
Achromobacter xylosoxidans 22 2.9 
Other species 120 15.7 
Table 1. Organisms cultured from the respiratory tract of Belgian CF patients [14]. 
 
Of course, in any discussion of the prevalence of individual CF pathogens age is an important 
factor (see chapter IV: Microbiology of the CF lung (“early and late” infectors)).  
 
Upper airway problems: 
Nasal polyps are found frequently in CF patients, the incidence raising from 10% to 32%. 
Nasal obstruction is the most common symptom and reason for removal of polyps, but 
recurrence rate is high. 
The sinuses are infected in more than 90% of patients with CF, but bacterial flora does not 
always correlate with the lower airways. It is however important to consider that sinuses may 
act as a long term reservoir, and that they are an important risk factor following lung 
transplantation.  
 
Growth, nutritional status and pancreatic insufficiency: 
Until relatively recently many children with CF were of below normal weight and height and 
had delayed puberty. Those who reached adulthood were of relatively short stature. 
Malabsorption due to pancreatic insufficiency leads to deficiencies of  the fat-soluble vitamins 
(vitamin A, D, E and K), some minerals and trace-elements (such as Magnesium and Zinc),  
essential fatty acids (EFA) and antioxidants (such as vitamin C and E, β-carotene and 
Selenium). 
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 Factors which contribute to the poor nutritional status of many CF patients include an 
inadequate energy intake, the often severe and rarely completely controlled intestinal 
malabsorption and  the increased energy demands resulting from chest infection. 
Not all CF patients have intestinal problems, about 15% are pancreatic ‘sufficient’. However 
with increasing age, these patients can eventually become pancreatic insufficient, especially 
those with more ‘severe’ mutations.  
Patients with pancreatic insufficiency tend to have more severe lung disease. 
  
Diabetes mellitus: 
Estimates of prevalence of diabetes mellitus vary from 2.5 to 12% of patients, increasing with 
age.   
 
Liver disease: 
About 20% of CF patients have biochemical, echographic or clinical evidence of liver disease, 
and 5% have overt clinical liver disease, rising from 0.3% in under 5-year-olds to 9% in those 
older than 16 years. Overt clinical liver disease is commonly associated with serious 
nutritional problems.  
 
Pancreatitis: 
Acute infection/inflammation of the pancreas is almost solely described in pancreatic 
sufficient patients. 
 
Other endocrine abnormalities: 
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 Insulin-like growth factor 1 is an anabolic hormone and an important marker of nutritional 
status, liver function and linear growth. A diminished concentration and a correlation with the 
height score is described in CF patients. 
Recent work on leptins, involved in controlling body weight and energy expenditure, showed 
their beneficial effect on nutritional CF problems.   
 
Fertility problems: 
Male reproductive and sexual health:  
Infertility is thought to occur in 98% of men with CF, due to the aberrant development of the 
reproductive portion of the wolffian duct, resulting in absence or atrophy of the vas deferens, 
vesiculae seminales, ejaculatory duct and epididymis. 
The ejaculate is acidic and of low volume. Sexual potency is normal, however severe disease 
can impair testicular function. Isolated CBAVD can be seen as a ‘mild’ form of CF. 
 
Female reproductive and sexual health: 
Women with CF have anatomically normal reproductive tracts, but abnormalities of cervical 
mucus have been described. The formation of thick, tenacious cervical mucus may reduce 
sperm penetration. 
Women with severe respiratory disease and poor nutritional status are likely to have 
amenorrhoea and anovulatory cycles. 
With the improved respiratory function, better nutrition and longer survival contemporary 
young women have higher fertility rates than previous generations. 
 
Osteoporosis: 
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 Osteoporosis is a systemic skeletal disease characterized by low bone mass and micro 
architectural deterioration of bone tissue, with consequent increase of bone fragility. 
The risk factors for developing osteoporosis in CF are: vitamin D and calcium malabsorption, 
low body weight, decreased physical activity, delayed puberty, male hypogonadism and 
amenorrhoea, glucocorticoid usage, diabetes, chronic infection with increased cytokines and 
organ transplantation. 
 
Other organ systems: 
Systemic secondary amyloidosis is a complication of long-standing chronic inflammatory 
diseases due to infection, auto- immune disease and malignancies. Although a high proportion 
of the patients are chronically infected by P. aeruginosa, only around 20-30 cases of 
amyloidosis are described. 
Thyroid gland abnormalities are described, and not only in those patients treated with iodide 
as expectorant. 
Kidney disease such as nephrocalcinosis and nephrolithiasis is sporadically seen. 
Secondary damage due to aminoglycoside usage is obvious. 
 
d. Genetic epidemiology: 
 
The most common disease-causing mutation is ΔF508 (a deletion on chromosome 7 which 
results in the loss of a phenylalanine residue at position 508 of the putative protein); 
This mutation was first identified on 68% of French speaking Canadian CF patients’ 
chromosomes [15]. Table 2 presents the Belgian data. 
The frequency of the ΔF508 mutation differs significantly among various ethnic groups. The 
highest incidence is reported in Denmark (82% of CF mutations), whereas the lowest 
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 incidence occurs in Algeria (26.3%). In Northern Europe, the overall incidence is 
approximately 71%, whereas in Southern Europe it varies between 45 and 55% [16].  
 
CF is more common in Caucasian populations, and the incidence varies also within countries. 
For the UK the incidence is estimated at 1/2400, whereas in Belgium it is 1/3700. 
In Israeli Jews (Europe-America) the incidence is 1/3300, in Jews of Asia and Africa 1/9400, 
in American blacks 1/17000, in the oriental population (Hawai) 1/90000 and in Japan it is 
limited to 1/320000-680000. 
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 Table 2. Distribution of mutations in the Belgian 
CF population 2003 [14]. Mutations n % 
∆F508 1139 71.4 
G542X 49 3.1 
N1303K 40 2.5 
1717-1G->A 23 1.4 
3272-26A->G 18 1.1 
R117H 15 0.9 
S1251N 14 0.9 
2789+5G->A 12 0.8 
L927P 12 0.8 
W1282X 10 0.6 
∆I507 10 0.6 
R553X 9 0.6 
3849+10kbC->T 8 0.5 
A455E 8 0.5 
poly-T tract variations 7 0.4 
E60X 7 0.4 
394delTT 7 0.4 
2183AA->G 6 0.4 
Y913C 5 0.3 
G970R 5 0.3 
W401X 5 0.3 
G85E 4 0.3 
R334W 4 0.3 
Other 85 5.3 
Unidentified 94 5.9 
Not determined 10  
Total 1624 100.0 
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 Chapter III.  Pathophysiology of respiratory infection in CF 
 
a. Introduction: 
The CF gene product, which is the membrane-bound  CFTR protein, has been shown to be the 
chloride-ion channel regulating the transport of chloride ions across fluid-transporting 
epithelial cells such as exocrine glands. This leads to altered secretions (salty sweats and 
dehydrated, sticky mucus), blocked ducts and reduced non inflammatory defence of the 
respiratory tract, which in turn leads to increased inflammatory defence and subsequently to 
lung damage.    
Before the introduction of penicillin, almost all patients died before the age of 5 years, due to 
Staphylococcus aureus (S. aureus) infection. 
The most significant CF pathogen during the last 3 decades remains P. aeruginosa, which 
causes most of the morbidity and mortality of these patients. 
Below, an overview of the pathophysiology of infections in cystic fibrosis will be given  [1].  
 
b. Impact of defective CFTR on airway physiology and mucociliary clearance 
The impact of aberrations in transepithelial ion flow on the ionic composition and volume of 
airway surface liquid (ASL) in CF due to dysfunctional or absent CFTR is an active topic of 
investigation. ASL consists of two layers above the epithelial surface: a mucus layer and a 
periciliary liquid layer (PCL) with a height of the extended cilium (  7 µm). The PCL volume 
is tightly regulated to provide a low-viscosity solution for ciliary beat and to lubricate gel-
forming mucins secreted from the cell surface. The mucus layer consists of high molecular 
weight mucins whose properties are altered by water content, ion concentrations, and pH. The 
mucin gel binds a wide variety of particles for ultimate clearance from the airway (Figure 4).  
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Figure 4. Pathogenic events hypothesized to lead to chronic P. aeruginosa colonization.  
(A) In normal airway epithelia, the presence of a low-viscosity periciliary layer (PCL) of normal volume 
promotes efficient mucociliary clearance. A normal rate of epithelial cell oxygen consumption (QO2) results in no 
gradient in the partial pressure of oxygen (pO2) within the airway surface liquid (ASL). In the CF airway, (B) 
isotonic volume depletion of the PCL (denoted by downward arrows and bent cilia) results in reduced 
mucociliary transport (bidirectional horizontal arrow) and (C) persistent mucus hypersecretion (denoted by 
upward arrows from secretory gland/goblet cell units) with time increases the height of the luminal mucus 
layer/plugs. Elevated CF epithelial QO2 generates steep hypoxic gradients (dark colour in pO2 bar) in the 
thickened mucus layer. (D) P. aeruginosa bacteria deposited on mucus surfaces penetrate actively or passively 
(due to mucus turbulence) into hypoxic zones of the mucus masses. P. aeruginosa adapt within the hypoxic 
environment with increased alginate expression and the formation of microcolonies with potential evolution into 
biofilms. (E) Increased P. aeruginosa microcolony density and the presence of neutrophils render the mucus 
layer more hypoxic. P. aeruginosa microcolonies within the hypoxic mucus plugs resist host lung defenses, 
including neutrophils, and result in chronic airway infection [17].  
 
Two competing hypotheses have been proposed: (1) the isotonic "low volume" hypothesis 
with abnormalities in mucociliary clearance, and (2) the "compositional" hypothesis with 
increased ASL salt concentrations in CF, resulting in inactivation of salt-sensitive 
antimicrobial peptides [18] (Figure 5).  
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 With regard to the first hypothesis there is no final consensus on the tonicity of ASL in 
subjects with CF relative to healthy control individuals. Technical limitations of collecting and 
assaying ASL from the upper and lower airways are a significant obstacle. It is also uncertain 
whether ASL composition varies along the respiratory tract (i.e., from nasal epithelium to 
distal airways), in response to chronic inflammation and infection, and within local 
microenvironments such as submucosal glands or mucus plugs. There is increasing evidence 
from nasal and bronchial epithelium derived from human and animal sources, that ASL is 
similar in healthy control individuals and subjects with CF and is isotonic [19-23]. 
However, using a novel isotopic technique, one investigator suggests that normal ASL 
concentrations of sodium and chloride are approximately 50 mM and that the ASL 
concentrations of these ions are elevated to approximately 100 mM in CF [24]. Therefore, the 
"compositional" hypothesis has not been entirely rejected, especially when considering local 
microenvironments such as submucosal glands.   
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 Figure 5. Two hypotheses of how ASL differs in healthy and CF lungs. (A) The low-volume hypothesis postulates 
that normal ASL (A1) has salt levels approximately equal to plasma. In CF (A2), the removal of CFTRs 
inhibition of epithelial sodium channels (EnaC) results in abnormally elevated isotonic fluid absorption, which 
depletes the ASL and leads to reduced mucociliary clearance. Key features of the low-volume model are the 
parallel pathway for Cl- via shunt pathway(s) and inhibition of ENaC via CFTR. (B) The high-salt hypothesis 
postulates that normal ASL has low levels of salt as a result of salt absorption in excess of water (B1). Even 
though the epithelium is water permeable, salt is retained in thin surface films by some combination of surface 
tension impermeant osmolytes. In CF (B2), salt is poorly absorbed resulting in excessively salty ASL that 
inactivates endogenous, salt-sensitive antimicrobial peptides. Key features of the high-salt model are: the lack of 
an appreciable shunt Cl- conductance, central importance of CFTRs channel role, no specific role for inhibition 
of ENaC by CFTR, and a switch from isotonic volume absorption to hypertonic salt absorption as the surface 
layer thins and traps residual water. [1] 
With regard to the second hypothesis, it has recently become more clear that both the 
accelerated Na+ absorption and the failure to initiate Cl– secretion to the abnormal ASL 
volume plays an important role in the pathophysiology of CF. These abnormalities ultimately 
lead to depletion of the PCL layer and to the formation of thickened ("concentrated") mucus 
plaques and plugs adherent to CF airway surfaces [11].  
Mucociliary clearance is a primary innate airway defence that, relying to most studies, is 
reduced in CF. In CF, there is abnormal regulation of the periciliary liquid volume that 
contributes to reduced mucociliary clearance. Altered viscosity and regulation of submucosal 
gland secretion may also impair host defence. In addition, the reduced periciliary liquid 
volume promotes interactions between gel mucins in the mucus layer with cell-surface mucins 
that hinder clearance of particles from the airways. Clearance of particles from normal 
peripheral airways by mucociliary clearance can require up to 6 hours, and this can be 
significantly prolonged in CF airways. Endogenous antimicrobial peptides can suppress 
bacterial growth for 3 to 6 hours. Thus reduced mucociliary clearance in CF may contribute to 
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 overwhelming of the innate antimicrobial peptides by bacteria and thereby promote the initial 
endobronchial infection in young children. 
c. Impact of defective CFTR on initial and persistent P. aeruginosa infection 
The abnormal composition and mechanical properties of airway secretions does not explain 
the propensity for the CF airway to become colonized with only a limited number of 
bacterial pathogens, in particular, P. aeruginosa. There are several hypotheses to help us 
understand that association.  
- Abnormal bacterial adherence to epithelial cells (Prince hypothesis)? 
Initial infection may be related to increased P. aeruginosa adherence to receptors in 
the CF airway (Figure 4C). CF epithelial cells demonstrate greater adherence of 
piliated laboratory strains of P. aeruginosa compared with control cells, and 
expression of wild-type CFTR in CF cell lines results in reduced P. aeruginosa 
binding [25-27]. The degree of P. aeruginosa binding was greater in nasal scrapings 
from patients homozygous for F508 compared with compound heterozygotes or 
carriers [28]. The basis for this increased adherence of piliated P. aeruginosa to the 
apical surface of CF epithelial cells is proposed to be secondary to increased 
asialoganglioside-1 [25, 26, 29, 30]. Asialoganglioside-1 receptors are increased in 
cells expressing mutant CFTR and in areas of regenerating epithelium that are likely 
present in the inflamed CF airway [26, 29]. Asialoganglioside-1 however is not a 
receptor for clinical mucoid isolates without pili or flagella [29], and therefore this 
host–pathogen interaction may not be relevant to chronic P. aeruginosa infection.  
- CFTR: a receptor for P. aeruginosa internalisation (Pier hypothesis) ? 
In contrast with the former hypothesis that there is increased P. aeruginosa adherence 
to receptors in the CF airway, this hypothesis contradicts the former one and 
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 hypothezises that it is wild type CFTR that is a receptor for P. aeruginosa, leading to 
binding to airway epithelium for subsequent phagocytosis and clearance by 
desquamation [31-33]. Thus, reduced wild type CFTR leads to reduced P. aeruginosa 
binding, resulting in reduced P. aeruginosa clearance from the CF airway. This 
mechanism can initiate endobronchial infection. The complete LPS outer core is 
proposed to be the P. aeruginosa ligand that binds to wild-type CFTR. Nonmucoid 
clinical isolates of P. aeruginosa, but not mucoid isolates, seem to bind to CFTR and 
are cleared more rapidly from wild-type versus transgenic CF mice and overexpression 
of CFTR in transgenic mice resulted in increased clearance of P. aeruginosa from the 
lung. P. aeruginosa adaptation within the CF airway is associated with modifications 
to LPS structure: the specific LPS structures required for P. aeruginosa binding to 
CFTR have not been fully elucidated.   
Epithelial phagocytosis probably does not play a role in established infection however, as 
mucoid P. aeruginosa and S. aureus are observed primarily within endobronchial mucus and 
not adherent to the epithelium. 
 
There are some arguments to prefer the Pier hypothesis and to refute the Prince theory:  
1. Increased adherence is only seen when cells from patients homozygous for ΔF508 
allele are used, yet patients with other alleles or compound heterozygotes for mutant 
ΔF508 alleles are just as severely affected by  P. aeruginosa. 
2. The major bacterial adhesin to asialo GM1 is proposed to be the bacterial pilus, yet the 
crystal structure of the P. aeruginosa strain PAK pilin subunit has been solved 
recently, and the site previously identified to bind asialo GM1 was not found to be 
surface-exposed on the pilin subunit. 
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 3. In the Prince theory, bacterial adherence to asialo GM1 is confirmed by commercially 
purchased rabbit antisera. These, however, contain high titers of antibodies to P. 
aeruginosa and other antigens (for instance bovine serum albumin). Therefore, one 
must question the conclusions that there are increased levels of expression of asialo 
GM1 on CF cells, because of the lack of specificity of the antisera to asialo GM1. 
 
 - Innate immunity and persistence of bacterial infections. 
Innate immune responses provide the first line of defense to airway infection together 
with mucociliary clearance. Submucosal glands, goblet cells of the large airways, 
Clara cells within the small airways, and epithelial cells secrete proteins and peptides 
into the ASL that can kill a broad spectrum of bacteria or modulate the host 
inflammatory response [34]. There is no evidence for a primary defect in the 
production of these antimicrobial peptides residing in the CF ASL, except for 
mannose-binding lectin. Decreased concentrations of mannose-binding lectin, 
observed in individuals with polymorphisms in the mannose-binding lectin gene may 
contribute to more rapid decline in pulmonary function and poor survival in patients 
with CF colonized with P. aeruginosa and Burkholderia cepacia-complex [35, 36].  
As explained above, the changed conditions in ASL and PCL can lead to inactivation 
of the antimicrobial peptides permitting initial bacterial colonization within the CF 
airway.  
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 - Acquired immunity. 
There is no evidence for a systemic immunodeficiency in CF to explain the chronic 
endobronchial infection. CF patients have no increase in the frequency or severity of 
infections outside of the respiratory tract and they have normal immune responses to 
standard immunizations. Patients with CF mount a significant humoral response to P. 
aeruginosa antigens, and there are emerging data that serum antibodies directed 
against whole-cell P. aeruginosa lysates or specific P. aeruginosa antigens can be the 
first markers of P. aeruginosa infection in young children with CF [37-38]. Patients 
with chronic P. aeruginosa infection demonstrate high concentrations of antibodies 
directed against multiple P. aeruginosa antigens. However, despite this early and 
sustained immune response to P. aeruginosa, the host is generally unable to clear P. 
aeruginosa from the airways.  
However, the potential to eradicate non-mucoid P. aeruginosa, and to delay 
transformation to mucoid species, makes ascertainment of the initial P. aeruginosa 
infection one of the highest priorities in clinical CF management. Traditional methods 
of  P. aeruginosa identification (relying on microbiology) leave much to be desired, 
especially in youg children with CF. Thus, Pseudomonas serology could have a 
potential diagnostic value, in these cases of “early” infection. 
A recent editorial [39] illustrates the controversy on this subject, by commenting two 
publications with contrasting results [40, 41]. A German research group [40] states 
that regular determination of serum antibodies is reasonable in CF patients with 
negative or intermittent P. aeruginosa colonisation, but not in those with a positive P. 
aeruginosa status. Based on their experience that a rise in antibody titers indicates 
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 probable infection, they recommend eradication treatment, even in the absence of 
positive culture. 
This is however in sharp contrast with the findings of a Dutch group [41] that 
concludes that “although serological tests are sensitive for identification of chronic P. 
aeruginosa infection, the failure of serological tests to detect early colonisation in 
young patients emphasises the need for continued reliance on cultures”. 
The reasons for these contrasting results could be many [39]. Both groups used the 
same commercially available ELISA test system, but used different cut off values. 
There were design differences (different periods of repeated measurements). To 
evaluate whether CF patients are P. aeruginosa-free, intermittently infected or 
chronically infected, P. aeruginosa-positive culture remains the “gold standard”. In 
the German study, only 42% of patients could expectorate sputum and thus 
nasopharyngeal swabs were used for the remaining patients. In the Dutch study the 
results were based on a sputum cultures in 75% of patients. The greatest difficulty in 
studying young children with CF-that is the problem of culturing lower respiratory 
tract secretions-will continu to plague these kind of investigations. For these reasons, 
non-culture based methods such as serological tests and polymerase chain reaction 
require further research and evaluation. 
 
d. Establishment of chronic infection  
With slow proliferation of bacterial micro-organisms and biofilm formation, the stage for 
persistent infection of adherent mucus is set. The growth of biofilms in thickened mucus 
plaques creates advantages to the bacteria. Migratory neutrophils penetrate difficultly into the 
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 thickened mucus plaques, and the diffusion of antimicrobial activities into the thick mucus 
plaques is limited. This evasion of secondary defense mechanisms, coupled with the 
competitive advantages for bacteria in the biofilm growth modus, leads to the scenario of 
persistent infection. Bacterial growth in densities sufficient to generate biofilms will probably 
deplete the mucus plaques of virtually all oxygen, rendering the infected material on airway 
surfaces anaerobic (see Figure 4, above). 
 The likelihood that CF airway infections reflect an anaerobic mucus/mucopurulent surface 
infection has broad implications for the therapy of CF infectious lung disease [11]. The 
sensitivity of many antibiotics is very different when bacteria are grown under aerobic versus 
anaerobic conditions. For instance, it has been shown that the sensitivity of P. aeruginosa to 
macrolides shifted one to two logs to the left under anaerobic conditions compared with 
aerobic conditions [42].  
e. Role of cytokines and inflammatory mediators in cystic fibrosis 
 Airway disease in cystic fibrosis is characterised by chronic infection and an inflammatory 
response dominated by a neutrophilic infiltrate. There is incomplete understanding of the 
relationship between the abnormal CFTR gene product and the development of inflammation 
and progression of lung disease in CF.  
The review by Courtney, Ennis and Elborn [43] gives an overview of the role of cytokines 
and their dysregulation in the pathogenesis of lung disease in CF. 
Airway inflammation in CF seems to be associated with increased production of pro-
inflammatory cytokines in the lung. Airway epithelial cells, macrophages, and neutrophils are 
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 all capable of producing cytokines. Several studies have found elevated concentrations of pro-
inflammatory cytokines such as interleukin-1 (IL-1), IL-6, IL-8, and tumour necrosis factor-
alpha (TNFα) in the sputum and bronchoalveolar lavage fluid (BALF) of patients with CF. 
Their synthesis is promoted by the transcription factor nuclear factor-κB (NF-κB), which 
plays an important role in intracellular signalling for the production of pro-inflammatory 
cytokines. IL-10, IL-1 receptor antagonist protein (IRAP), and soluble TNFα receptor 
(TNFsR) are anti-inflammatory cytokines that are relatively down-regulated in CF airway 
cells. The principle action of IL-10 is to increase the synthesis of I-κB, the inhibitor of NF-
κB. Down regulation of IL-10 leads to increased pro-inflammatory cytokines due to less 
inhibition of NF-κB actions. 
The T helper (Th) cell clones into either Th1 (IFN-γ-producing) or Th2 (IL-4-, IL-5-, or IL-
10-producing) cells and thus, the outcome of chronic infections has been thought to depend on 
the differences in the specific Th cell response. Patients with a higher expression of IFN-γ in 
bronchial biopsies seem to have milder disease. 
In patients, with chronic infection, those with higher IFN-γ production had better lung  
function. 
In chronic P. aeruginosa lung infection in mice with a pulmonary Th1 response, there is 
lower mortality, faster clearance of bacteria, and milder lung inflammation in comparison to 
mice reacting with a Th2 response. 
Peripheral blood mononuclear cells from patients stimulated with P. aeruginosa antigen 
demonstrated a Th2-dominated response in CF patients with stable chronic P. aeruginosa 
lung infection as compared to CF patients without chronic P. aeruginosa lung infection. The 
predominance of a Th1 or Th2 response is thought to depend on the type of dendritic cell that 
is responsible for the priming of the T cells to new antigens.  
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 As mentioned above, the review on CFTR by Mehta [10] also discusses the possible links 
between abnormal fatty acid turnover and inflammatory cascades that are abnormal in cystic 
fibrosis. 
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 Chapter IV. Microbiology of the CF lung 
Since chronic infection of the lower airways in CF is the most important cause of death, it is 
very important to know the different etiologic agents of these acute exacerbations, which will 
lead by time to chronic infection. 
Acute exacerbations of chronic respiratory disease in CF patients were found to be caused by 
bacteria (63%), bacteria and virus (13%) and virus (6%), whereas no etiologic agent could be 
detected in 18% of the exacerbations [12]. 
Diagnosis of respiratory virus infections is currently achieved by detecting of virus antigens 
using the ELISA technique, or by showing the presence of raised antibody titers against 
viruses. Nowadays, the polymerase chain reaction (PCR) for detecting viral DNA or RNA is 
also applied in this diagnostic field. Viruses as influenza A and B, parainfluenza virus 1 and 3, 
rhinovirus, adenovirus and respiratory syncytial virus (RSV) are known to cause 
exacerbations in CF patients [12]. 
CF has a unique set of bacterial pathogens that are frequently acquired in an age-dependent 
sequence. The pattern of age-specific prevalence as well as overall prevalence of these 
pathogens in the CF population in the United States is demonstrated in Figure 6 from the 
Cystic Fibrosis Foundation Patient Registry data [44]. Of the organisms causing infection in 
CF, only S.  aureus may be pathogenic in immunocompetent individuals. P. aeruginosa, B. 
cepacia complex, nontypeable H. influenzae,  S. maltophilia, and A. xylosoxidans are all 
considered opportunistic pathogens. Other organisms seen in CF, generally non pathogenic in 
the healthy host, include Aspergillus and nontuberculous mycobacteria.  
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 Figure 6. Age-specific prevalence of airway infections in patients with CF. Organisms reported to the U.S. Cystic 
Fibrosis Patient Registry, 2001. Overall percentage of patients (all ages) who had at least one respiratory tract 
culture performed in 2001. 
 
We can divide the infecting organisms in ‘early infectors’ and ‘late infectors’. 
 
Early infections in CF airways are most frequently caused by S. aureus and H. influenzae, 
organisms that may be seen in other young children with chronic respiratory illnesses and in 
adults with non–CF bronchiectasis. S. aureus is often the first organism cultured from the 
respiratory tract of young children with CF. Whether S. aureus is really harmful for CF lungs 
continues to be debated. Also MRSA (methicilline resistant Staphylococcus aureus) is an 
emerging problem in CF patients.  
H. influenzae is also isolated from the respiratory tract early in the course of CF. The H. 
influenzae, infecting patients with CF, is non typeable, thus not prevented by childhood 
immunization against H. influenzae type b. The role of H. influenzae in progressive airway 
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 infection and inflammation in patients with CF has not been clearly demonstrated, although it 
is known to be pathogenic in patients with non–CF bronchiectasis.  
P. aeruginosa has been regarded in the previous decades as a ‘late infector’. However several 
recent studies show that infection appears to occur much earlier than believed previously [44, 
45, 46]. In a natural history study of patients with CF in the first 3 years of life, the mean age 
of detection of an antibody response to P. aeruginosa was approximately 15 months, whereas 
the mean ages of first positive upper and lower airway culture were approximately 21 and 23 
months, respectively. In total 29 of the 40 patients demonstrated Pseudomonas aeruginosa 
during their first 3 years [45]. In a study of 68 patients with CF, identified by neonatal 
screening, antibody responses to P. aeruginosa were identified, on average, nearly 12 months 
before positive oropharyngeal (OP) cultures (lower airway bacteriology was not available in 
these individuals) [46]. Up to 80% of patients with CF are eventually infected with this 
organism, and acquisition of the organism is associated with clinical deterioration. The source 
of P. aeruginosa isolates in patients with CF has not been clearly established. There is a wide 
distribution of P. aeruginosa genotypes that have been demonstrated in young children [45], 
suggesting acquisition from environmental reservoirs. Comparison of genotypes from upper 
and lower airway sources collected simultaneously from patients demonstrates that distinct 
genetic strains may colonize different anatomic sites in the CF airway [47].  
Whereas early isolates phenotypically appear much like environmental isolates, later isolates 
are more resistant to antibiotics and frequently mucoid. Altough the presence of microcolonies 
of  P. aeruginosa was already described in 1980 [48], the existence of biofilms in CF has  
been fully recognized only recently (see Chapter 3). Biofilms are sessile communities of 
bacteria on surfaces (Figure 4) with following characteristics: slow growth of organisms, 
stimulation of production of antibodies that are ineffective in clearing bacteria and inherent 
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 resistance to antibiotics. Therefore it becomes impossible to eradicate biofilm infections even 
in hosts with intact immune systems.  
The presence of P. aeruginosa biofilms in infected CF airways was first suggested because of 
the quorum-sensing signals that the organisms produce to signal cell-density–dependent gene 
expression. In addition electron microscopy has demonstrated organized clusters and 
microcolonies of P. aeruginosa in expectorated CF sputum consistent with biofilm formation. 
Subsequently, the presence of local hypoxia within mucus plaques in the airways has been 
suggested to increase Pseudomonas alginate production, which may lead to increased biofilm 
formation. How biofilm formation develops is described in Chapter 3, Figure 4.  
Recently the genome of a laboratory strain of P. aeruginosa, PAO1, has been sequenced. P. 
aeruginosa has a very large genome (6.3 Mbp) [49]. This complete genome offers the 
potential for a tremendous ability to adapt to multiple different environments, including the 
CF airway. P. aeruginosa isolated from CF sputa have even larger genomes than the 
laboratory strain, PAO1, suggesting that they have acquired new genes during their 
adaptation, in addition to alterations in those already present [50].  
A high frequency of hypermutability has been identified in P. aeruginosa isolates from 
patients with CF. This is likely caused by the specific CF airway with large numbers of 
infecting organisms and compartmentalization of infection, combined with ineffective host 
defenses and ongoing antibiotic selective pressure.  
True late infectors are B. cepacia-complex, S. maltophilia, A. xylosoxidans, nontuberculous 
mycobacteria and fungi including Aspergillus. 
 B. cepacia is the most feared because of its association with the B. cepacia syndrome, which 
can lead to death due to bacteremia and fatal necrotizing pneumonia. Most patients however 
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 have a more chronic course with decline in lung function and increased mortality. B. cepacia 
is not a single species but rather a group of closely related species, named "genomovars"; 
thus, the organism should be called B. cepacia complex. The vast majority of CF airway 
infections with B. cepacia complex are caused by genomovars II (Burkholderia multivorans), 
III (Burkholderia cenocepacia) and V (Burkholderia vietnamiensis) [51, 52]. Genomovar III 
has been shown to spread in epidemics. In this thesis,  B. cepacia complex was not studied, 
since the incidence of chronic infection with this organism is low in our centre. 
S. maltophilia and A. xylosoxidans are encountered more frequently than B. cepacia in CF 
patients with advanced lung disease, but are thought to be less virulent. There is at present 
limited evidence for a correlation between infection and outcome. Chapter VII  of this work 
will focus on possible patient-to-patient transmission and clinical impact of A. xylosoxidans. 
In a group of 557 CF patients Tan and co-workers [53] reported a prevalence of 2.3% 
considering only patients with at least three positive cultures over a period of 6 months. 
 In a prospective multi centre German study Steinkamp et al. [54] reported a prevalence of 
1.1% among 1419 CF patients.  
 In the Belgian CF register 2003 [14], gathering 865 patients, a prevalence of 2.9% is 
mentioned, collecting all patients with at least one positive culture during the year 2003. 
These prevalence data can however be disputed, since misidentification of gram negative non-
fermenters cultured from CF sputum may occur, because of the diversity of colonial 
morphologies and biochemical reactivity encountered.  For instance, in one study, 
misidentification of  11% of A. xylosoxidans strains was reported [55]. 
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 Nontuberculous mycobacteria have been increasingly reported from the respiratory secretions 
of patients with CF. The species most commonly isolated are Mycobacterium avium complex 
and Mycobacterium abscessus. In the US 13% of patients have nontuberculous mycobacteria 
in their sputum. These patients are older and have a higher frequency of S. aureus and a lower 
frequency of P. aeruginosa compared with culture-negative control CF subjects.  
Since the CF population is frequently exposed to broad-spectrum antibiotic therapy, fungal 
colonization of the CF airway late in disease progression occurs frequently. Candida spp. are 
the most frequent colonizers and are usually considered to be harmless commensals. However, 
Aspergillus spp., most frequently Aspergillus fumigatus, are isolated from more than 25% of 
patients [56]. Invasive infections caused by Aspergillus are rare in the immunocompetent non 
transplant CF population, but allergic bronchopulmonary aspergillosis (ABPA) can be a 
significant problem, wich occurs in about 10 % of CF patients [12]. The cause of ABPA is not 
an invasive fungal infection but a type I and III hypersensitivity reaction against allergens from A. 
fumigatus in the environment, which leads to a clinical syndrome with wheezing, pulmonary infiltrates and, if 
untreated, bronchiectasis and fibrosis. Exposure of the airways to high levels of Aspergillus  
allergens and reduced mucociliary clearance in CF, may be a key element in the development 
of ABPA, especially in atopic patients.  
Other molds that have been reported from CF respiratory samples include Scedosporium 
apiospermum  and less frequently Wangiella dermatitidis and Penicillium emersonii. Their 
clinical significance is unknown. 
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Chapter V: Questions to be anwered 
As mentioned in the introduction, our concern for patient-to-patient transmission of P. 
aeruginosa amongst the CF patients residing in the CF rehabilitation centre of 
Zeepreventorium, De Haan, led to a first study (p. 73) in order to answer the following 
questions:  
 
1. Do the P. aeruginosa colonized patients carry a ‘unique’ or a ‘shared’ genotype?  
     (In other words is it probable that patient-to-patient transmission has occurred in the  
      past?) 
2.   Do the patients carry one or more genotypes? 
3.   Do the patients acquire a ‘new’ genotype during their stay? (is it possible that 
      patient-to-patient transmission has occurred during the study period?) 
4. Do patients’ genotypes correspond with P. aeruginosa genotypes found in the   
      rehabilitation centre environment? (can the patients become infected or co-infected  
      by a P. aeruginosa genotype, originating from the environment of the rehabilitation  
      centre?) 
 
The second study (p. 83) tried to set up a national database, in order to answer the following 
questions: 
 
5.    Do the Belgian P. aeruginosa colonized patients carry a ‘unique’ or a ‘shared’  
        genotype? (is it probable that patient-to-patient transmission has occurred in the 
   past?) 
6.     Do the patients carry one or more genotypes? 
7.     Do the patients carry the same genotype, when sampled again, one year later? 
8. When patients share the same genotype (= cluster type, see later), is there a    
        correlation with the intensity of social contact? 
 
During the study in the CF rehabilitation centre we noticed that many of the P. aeruginosa colonized patients also 
seemed to be infected or even co-colonized with A. xylosoxidans. To examine the occurrence 
and transmissibility of this organism within CF patients, we set up a study to compare 
genotypes of A. xylosoxidans in the same population in the rehabilitation centre. ( p. 113). 
This study will answer following questions:  
 
9. Do the patients, chronically infected with P. aeruginosa and also co-infected or 
even co-colonized with A. xylosoxidans, carry a ‘unique’ or a ‘shared’ genotype 
of the latter organism? (is it probable that patient-to-patient transmission has  
         occurred ?) 
10.    Do the patients carry one or more genotypes of A. xylosoxidans? 
11.    Do the patients acquire a ‘new’ genotype of A. xylosoxidans during their stay?    
         (is there possible patient-to-patient transmission during the study period?) 
 
The clinical significance of this organism is unclear and until now, there is limited 
evidence for necessity of treatment. Therefore we set up a retrospective case control study (p. 
120)  to answer following questions:   
 
12. What is  the prevalence of A. xylosoxidans infection (= at least one positive culture) in
 
          our CF centre and what is the prevalence of colonization in our CF centre (= at least 3                                 positive cultures during a period of 9 months)?                      13.                       What is the clinical impact of A. xylosoxidans colonization?  
 
 Chapter VI. Molecular typing techniques 
 
Methods used for discrimination of genera, species and isolates can be divided into 
phenotypic and genotypic procedures. 
 Phenotypic procedures take advantage of biochemical, physiological and morphological 
phenomena such as cell and colony morphology, cell wall staining properties and the ability 
of a microbial species to grow under a given set of environmental conditions (e.g. 
temperature, oxygen dependency, osmolarity and the need for certain nutrients).  
Until the early nineties, typing of P. aeruginosa for epidemiologic purposes has traditionally 
relied on bacterial phenotypic characteristics, such as serospecificity of lipopolysaccharides 
(LPS), susceptibility to bacteriophages and antimicrobial agents, and bacteriocin production 
and susceptibility. 
Although effective in certain clinical settings, some of these methods have been found to be 
inadequate under conditions in which P. aeruginosa undergoes phenotypic conversion (see 
Chapters III and IV: formation of biofilm, mucoid strains). Furthermore P. aeruginosa strains 
of CF patients are endowed with rough LPS, which renders them refractory to typing with 
systems that rely on agglutination with antisera or on phage susceptibility. A multicentre 
comparison of methods for typing strains of CF patients [57] showed that the chromosomal 
DNA restriction fragment length polymorphism analysis (RFLP) had the greatest 
discriminatory power, in comparison with 10 phenotypic techniques. 
Therefore genotyic procedures were further developed. The starting point of these analyses is 
that the genome of each individual (and also each germ) is unique. The drawback of these 
restriction digestion based genotypic typing techniques are the need for a high degree of 
technical skills, and for a large quantity of high-quality DNA or RNA. Therefore enzymatic 
amplification of nucleic acid sequences has been applied increasingly for genotyping.  
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The PCR (Polymerase Chain Reaction) is the prototype nucleic acid amplification method, 
and it has been extensively evaluated for genotyping [58]. This technique has evolved from a 
laborious and relatively insensitive assay into an extremely sensitive and highly flexible 
procedure, since the discovery of thermotolerant DNA polymerases and the development of 
automated thermal cyclers.  
The basis of PCR fingerprinting is the amplification of polymorphic DNA through specific 
selection of primer annealing sites. Either constant primer sites bridge a single variable 
sequence domain or primers detect consensus sequences with variable distribution in the 
DNA. Differences in the distance between primer-binding sites or in the presence of these 
sites lead to synthesis of amplified DNA fragments which differ in length. These differences 
can be detected by simple procedures such as gel electrophoresis or chromatography. 
Different PCR fingerprinting techniques have been developed and different names have been 
used for identical techniques. Terms such as amplification fragment length polymorphism 
(AFLP), arbitrarily primed PCR (AP-PCR), DNA amplification fingerprinting or random 
amplification of polymorphic DNA (RAPD) are often used indiscriminately and create a 
‘Tower of Babel’ phenomenon. In a letter to the editor in the Journal of Clinical Microbiology 
in 2003 several CF physicians and microbiologists therefore emphasized the need for 
harmonization of techniques  and technique designations for genotyping clinical isolates of P. 
aeruginosa from CF patients [59]. Epidemiological research, comparable to our studies, has 
been done in the UK, Canada and Australia [60, 61, 62]. Most of these studies were based on 
Pulsed-Field Gel Electrophoresis (PFGE).  
Since our laboratory had already built up experience to genotype other species with RAPD 
and fAFLP, we chose to use these techniques [63, 64, 65]. 
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This choice was supported by a publication of Speijer et al. [66], who showed that AFLP 
analysis was the most discriminatory method. 
D’Agata et al. [67] concluded that AFLP is comparable to PFGE for P. aeruginosa isolates. 
 
The culture and genotyping procedure used for P. aeruginosa isolates are described in article 
1 and 2 (p. 73 and p. 83). 
 
Thus, in these studies, we estimated the genotypic diversity of P. aeruginosa colonies, 
initially by RAPD-analysis, and further with fAFLP-analysis for representative strains of the 
different RAPD-types observed for each patient. In all cases studied here, isolates with 
identical RAPD-fingerprints also had identical fAFLP-fingerprints, ensuring that no unrelated 
isolates were grouped into the same RAPD-genotype. For each patient, all of the RAPD-
products were always obtained during the same thermal cycling and electrophoresis run, to 
avoid differences due to the limited reproducibility of the technique. fAFLP is generally 
known to be more reproducible and - due to automated digitisation of the fingerprints – it 
makes possible large-scale comparison of hundreds of fingerprints, an endeavor that is 
impossible with RAPD-analysis. 
This combined approach of a rapid and cheap initial screening technique (RAPD-analysis) 
and a more sophisticated, more reproducible and digitized, but also more expensive and 
laborious technique (fAFLP-analysis), enabled us to genotype a large number of isolates in an 
affordable, reasonably convenient and a highly reliable and discriminatory manner. Moreover, 
the established library of fAFLP-fingerprints of CF P. aeruginosa strains can be used for 
further comparisons and long-term studies. 
For A. xylosoxidans (publication 3, p. 113) the same molecular methods were used, after 
identification of the organism, as described above. 
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 Chapter VII.  To segregate or not to segregate, that’s the 
question…! 
a. Introduction: literature data about transmissibility of pathogens other than P. 
aeruginosa and A. xylosoxidans. 
Since the early nineties, patient-to-patient transmission has been debated extensively. Saiman 
[69] discussed transmission of the several potential pathogens such as B. cepacia complex, P. 
aeruginosa, MRSA, S. maltophilia, A. xylosoxidans, nontuberculous mycobacteria and 
viruses. In 2004 a review of the same author updated the knowledge about transmission [70].  
For B. Cepacia complex studies from the USA, Scotland, England and Canada demonstrated 
transmission associated with close contact in social settings. These studies were performed by 
aid of accurate identification and molecular typing, provided by reference laboratories (i.e. the 
microbiology laboratory in Ghent, under the surveillance of Peter Van Damme). This 
knowledge led to disbanding of CF summer camps worldwide [71, 72]. 
Also transmission in health care settings has been documented, in association with 
hospitalisation, poor adherence to handwashing, contaminated respiratory therapy equipment 
and possibly contaminated hospital showers. Health care workers (HCW) do not seem to be a 
reservoir for B. cepacia complex strains (during a 3-month study 73 throat cultures from 
seven HCW remained negative [73]).  
While direct, indirect and droplet spread are demonstrated, true airborne transmission seems 
less likely. 
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 Some genomovars (as B. cenocepacia) are more likely to be spread from patient to patient and 
to be associated with epidemic outbreaks. B. cenocepacia is also known to replace less 
harmful members of the B. cepacia complex, in colonized patients. 
Numerous infection control measures that were successful in preventing transmission of B. 
cepacia in CF patients have been described, such as education, intervention in non-health care 
and health care setting, environmental decontamination and improvement of laboratory 
practises [70]. 
In summary, Burkholderia species can be transmitted from one patient to another. Thus, CF 
patients infected with B. cepacia complex must avoid close contact with other CF patients, 
including those already harbouring B. cepacia complex strains, to avoid acquiring potentially 
more virulent strains.  
 
S. aureus is often the first pathogen to infect the respiratory tract of CF patients. In the pre-
antibiotic era, the organism caused substantial morbidity and mortality in young children, 
however with effective antibiotic treatment, the burden of S. aureus colonization seems less 
threatening than of chronic infection with P. aeruginosa. 
The infection with S. aureus usually originates from the anterior nares. The same genotype in 
nose and subsequently in the lower airways has been demonstrated in non CF [74, 75] and CF 
patients [76]. In the latter study patients without recent antibiotic treatment had a higher 
prevalence of nasal colonization, than those, treated recently or than healthy controls. 
Staphylococcus aureus easily spreads in families with or without CF, but loss or replacement 
by another strain is frequently seen in family members. In CF patients however infection or 
colonization with the same strain has been documented (for at least 1 to 2 years) [77]. There is 
a significant increase of methicillin-resistant S. aureus (MRSA) in the CF population. In 2001 
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 7% of  registered American CF patients harboured MRSA. The clinical impact of MRSA in 
CF remains uncertain. 
One study showed that colonization is frequently brief [78], but another showed persistence of 
the same clone in a CF patient for several years [79]. Transmission from patient-to-patient can 
occur (also from non CF patients), thus preventive measures must be taken in in- and 
outpatient facilities.  
 
In the literature increasing prevalence of S. maltophilia has been reported over the last 
decade.In our CF centre the prevalence of S. maltophilia positive cultures was 14.3% in 2003, 
but only 2.3% of patients could be considered as chronically infected (at least 3 positive 
cultures during 6 consecutive months). 
Marchac et al. [80] reported a raising prevalence from 3.3% to 15% over a period of 10 years 
(’91-’99). 
Goss et al. [81] reported a prevalence of 8.7% for the period of 1991-1997, based on data of 
the US CF Registry. Talmaciu and co-workers [82] reported a prevalence of 19% from 1993 
to 1997. 
These papers tried to investigate the possible morbidity of this pathogen. Talmaciu and 
Marchac compared patients with at least one positive sputum culture with age-matched CF 
patients who had never been infected by S. maltophilia. Higher use of antibiotics seemed to be 
a risk factor in acquisition. 
Marchac could not show a deterioration in lung function, for the 2 years after acquisition. 
Goss could not show a difference in survival rate, during a 4 years follow-up study. 
Denton et al. [83] showed that this organism is widespread. The homes of both colonized 
(26% positive) and noncolonized (42% positive) CF patients, the hospital wards (32% 
positive) and the CF Clinic (17% positive) were contamined by Stenotrophomonas 
maltophilia. They also showed that clinics may even harbour the same clone for a year. 
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 Only a few studies have tried to define the transmissibility between patients, based on PFGE 
or PCR-techniques. 
Valdezate et al. [84] and Vu-Thien et al. [85] showed that most isolates were unique, but 
could persistent for a long time in an individual patient. 
Krzewinski et al. [86] demonstrated that in 3 of 6 US CF centres, two patients at each were 
infected by the same clone, although 2 pairs did not have an epidemiologic link.The Spanish 
study by Valdezate et al. [85] showed 3 patients carrying the same strain. 
 
Very few studies [87, 88] have used molecular typing techniques to examine the possibility of 
patient-to-patient transmission of Nontuberculous Mycobacteria. These studies could not 
demonstrate shared strains. 
 
 Patient-to-patient transmission has not been studied yet for fungi and molds, probably 
because it is almost certain that they are acquired from the environment, because they are 
ubiquitous (and thus unavoidable) in nature. 
 
Respiratory viruses are important pathogens in CF patients. These patients do not seem to be 
more susceptible to respiratory viral infections than their siblings or age matched controls [89, 
90] but the clinical course of the viral infection can be more severe (especially RSV, 
Influenza A and adenovirus infections). Transmission is obligatory from other infected 
persons, via direct, indirect and droplet infection. Prevention therefore is very difficult. 
Prophylactic strategies as administration of monoclonal antibodies against RSV 
(Paluvizumab) are on trial. 
Vaccination with an Influenza vaccine is recommended for CF patients, 6 months of age and 
older, and their close contact persons. 
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 b. Transmissibility of Pseudomonas aeruginosa 
Numerous studies have attempted to identify the initial source of P. aeruginosa in CF patients, 
but this remains unknown for most patients. P. aeruginosa has been shown to survive for 
prolonged periods; nonmucoid strains suspended in saline can survive on dry surfaces for 24 
h, mucoid strains can survive 48 h or more, and strains suspended in sputum of CF patients 
can survive on dry surfaces for as long as 8 days. Therefore it seems logical that patient-to-
patient transmission can occur. 
Potential sources of P. aeruginosa 
P. aeruginosa is widespread in the environment [91]. The organism has been isolated from 
several in- and outpatient sources, such as sinks and tap water in paediatric CF wards [92, 93], 
childrens’ toys and soap [94] and lung function equipment [95]. In some articles these 
environmental strains are compared genotypically with the patients strains. Occasionally, 
matches are found, but it always stays unclear whether the patients are the initial source of 
environmental contamination or vice versa [92, 96]. The study by McCallum et al. [97] 
however showed that a strain carried by 4 adults patients of the same CF centre could not be 
found from the environment (sinks, drains, toilets, showers, communal surfaces), although 
repeatedly cultured.  
The home nebulizer was also studied as a source of cross- infection: 25 to 50% of the studied 
nebulizers carried  P. aeruginosa [98, 99].  However, with the implementation of vigorous 
cleaning and disinfection (as recommended and taught by the CF centres), this high 
percentage of positive culture is expected to decrease. A recent Belgian study [100] evaluated 
the efficacy of 5 methods of disinfection of the mouthpieces and facemasks of nebulizers, 
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 indicating the concerne that exists among CF caregivers, regarding cross-infection from 
nebulisers.  
Other, more rare environmental sources of contamination are described: whirlpools, hot tubs, 
swimming pools or dental equipment. However, standard chlorinated swimming pools and 
dental equipment that is cleaned, disinfected and sterilized according to standard procedures 
do not harbour P. aeruginosa. 
The organism can also be cultured from the hands of  CF patients and HCW and studies even 
demonstrated a correlation between contaminated sink drains and hands, washed in these 
sinks [92, 101]. Droplet infection has been demonstrated by isolation from agar plates, placed 
1.5 to 3 feet (= ± 45 to 90 cm) from a coughing CF patient [92, 94]. Data about true airborne 
transmission, based on cultures of air samples, are controversial [94, 95, 102]. Until recently, 
it  was believed to be unlikely that P. aeruginosa, from the sputum of a CF patient, could 
remain suspended in the air long enough to enable transmission. The recent study by Jones et 
al. [103] however showed that epidemic P. aeruginosa strains were isolated from room air 
where patients performed lung function tests, nebulisation and airway clearance, and not from 
the inanimate environment. They concluded that aerosol dissemination may be the most 
important factor in patient-to-patient spread of epidemic strains. 
Patient-to-patient transmission 
Over the last 2 decades, worldwide, investigators tried to find evidence for patient-to-patient 
transmission. 
Early studies in CF siblings first demonstrated shared strains [94, 95, 104]. These studies were 
based on phenotypic methods. 
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 In the 1980s, the discovery of an epidemic, multidrug resistant strain of P. aeruginosa 
(confirmed by serotyping and pyocine typing and not yet by molecular techniques) in the 
Danish centre led to implementation of several infection control measures, such as a separate 
clinic for P. aeruginosa colonized patients and better hand hygiene for both patients and 
HCW. This led to a decreased incidence and prevalence of P. aeruginosa infection [105, 106, 
107].  
Genotyping techniques such as macro-restriction analysis in combination with pulsed-field 
gel electrophoresis, randomly amplified polymorphic DNA-analysis (RAPD) and 
amplification fragment length polymorphism (AFLP) have enabled reasonably accurate 
determination of the clonal relationship of P. aeruginosa isolates from patients within a CF 
centre or region [57, 66, 108, 109]. Nevertheless, different conclusions on the transmissibility 
of this pathogen have been drawn from two recent molecular epidemiological studies from 
two large centres - without segregation policy - in Canada [61] and in Australia [62]. 
The Australian cross-sectional study found a widespread clone of P. aeruginosa in 55% of the 
118 infected patients in a paediatric CF clinic. In contrast, the Canadian longitudinal study - 
over two decades – showed a low risk of patient-to-patient spread among 174 patients. 
Cross-sectional and longitudinal studies in Liverpool [97, 110], Manchester [103, 111, 112]  
and Sheffield [113] however have provided compelling evidence for transmission of highly 
transmissible strains.  
 
This raised once more the issue of the risk of cross-infection associated with CF holiday 
camps. Oyeniyi et al. [114] has shown that the five P. aeruginosa-negative patients who 
attended a winter camp in Spain together with 17 patients who were already colonized with P. 
aeruginosa, all acquired P. aeruginosa strains that were identical to strains carried by the 
colonized patients. Hoogkamp–Korstanje et al. [115] however reported an incidence of cross-
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 infection of  7% in previously P. aeruginosa- negative individuals (91 CF-patients who 
attended a CF-camp had respiratory cultures performed on arrival, after two weeks, after two 
months, and regularly thereafter). The authors concluded that the overall risk of acquisition 
was comparable to that occurring in the community, and that it was trivial compared with the 
obvious joy and social benefit derived from a holiday camp.  
A Brazilian study [116] in an outpatient CF-clinic also concluded that the risk of cross-
infection is low. 
 In the US, the time to acquisition of P. aeruginosa was shorter in infants diagnosed by 
neonatal screening than in those diagnosed by symptoms [117-120]. This was attributed to 
crowded clinic conditions, early use of aerosol equipment and early exposition to ‘centre 
care’, thus to patient-to-patient transmission. 
 
In summary, it has been demonstrated that CF patients can carry the same strain of  P. 
aeruginosa. 
There is more evidence for patient-to-patient transmission, than for acquisition of an epidemic 
strain from the environment. Patient-to-patient transmission is generally associated with close 
and prolonged social contact. 
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 i. Article 1: Epidemiology of Pseudomonas aeruginosa in 
a cystic fibrosis rehabilitation centre. 
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Epidemiology of Pseudomonas aeruginosa
in a cystic fibrosis rehabilitation centre
S.G. Van daele*, H. Franckx#, R. Verhelst", P. Schelstraete*, F. Haerynck*,
L. Van Simaey", G. Claeys", M. Vaneechoutte" and F. De Baets*
ABSTRACT: Pseudomonas aeruginosa is the leading pathogen in cystic fibrosis (CF) lungs.
Since there is great concern about clonal spread in CF centres, this study examined the
P. aeruginosa genotypes of colonised residents of a CF rehabilitation centre.
The isolates from the sputum of 76 P. aeruginosa-colonised patients were genotyped by
fluorescent amplified fragment length polymorphism on arrival and departure.
A total of 71 different P. aeruginosa genotypes were identified from 749 isolates. Forty-nine
patients had one genotype, 20 had two genotypes and seven had three. Forty-four patients had
one or more genotypes in common with other patients (i.e. cluster types). Thirty-two patients were
colonised by a single genotype not shared by any other patient. Thirty-eight of the 44 patients with
a cluster type already carried their cluster type strain(s) on arrival. Patient-to-patient transmission
could not be excluded for eight patients. For five of these, this infection was transient. None of the
environmental P. aeruginosa isolates had a genotype similar to the patients’ genotypes.
In summary, most patients were colonised by only one or two P. aeruginosa genotypes and the
risk of persistent patient-to-patient transmission was low during the study period (4%). Most
patients with a cluster-type strain carried this strain on arrival, indicating that transmission could
have happened in the past. No environmental contamination could be established.
KEYWORDS: Cystic fibrosis, epidemiology, Pseudomonas aeruginosa
P
seudomonas aeruginosa has been the lead-
ing pathogen in cystic fibrosis (CF) lung
pathology over the last three decades [1–3].
After initial infection, colonisation (as defined by
the criteria of DO¨RING et al. [4]) leads to the
destruction of lung tissue and reduction of lung
function, which may result in early death. The US
CF Foundation database reported that, in 1996, the
median survival of CF patients who were colonised
with P. aeruginosa was 28 yrs, while the median
survival for noncolonised patients was 39 yrs [5].
Loss of lung function has been clearly demonstra-
ted by KEREM et al. [6], who showed that patients
who were colonised with P. aeruginosa at the age of
7 yrs had a mean forced expiratory volume in one
second (FEV1) that was 10% lower than that of
noncolonised patients. Although the emergence of
a mucoid colonial morphotype is a more unfavour-
able prognostic factor than the presence of
nonmucoid P. aeruginosa [7], the latter forms an
important microbial reservoir from which mucoidy,
bacterial biofilms and chronic colonisation are
established [8].
Prevention of chronic P. aeruginosa colonisation
by appropriate antibiotic therapy is now common
practice once a ‘‘new’’ infection by the organism
has been identified [9, 10]. Currently, spread of
highly transmissible strains in some CF centres
has caused great concern, particularly when such
strains are multi-resistant and responsible for
primary infection [11–16]. Other studies, how-
ever, have failed to find evidence of clonal spread
[17–20].
In Belgium, many patients are referred to the CF
rehabilitation centre ‘‘Zeepreventorium’’ in De
Haan, for either a short or prolonged stay, in
order to learn specific physiotherapeutic techni-
ques, such as autogenic drainage. This situation
has led to justifiable concern among patients and
physicians about the risk of cross-infection.
Therefore, during 2001 and 2002, P. aeruginosa
isolates from 76 patients, together with environ-
mental isolates, were genotyped to investigate
the risk of patient-to-patient transmission.
METHODS
Patients
All 76 P. aeruginosa-colonised patients who
attended the rehabilitation centre from January
8 to April 30, 2001, and from September 1, 2001,
to October 31, 2002, with a total duration of stay
of 8,218 days (median 63 days), were enrolled in
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this study. Patients were aged 5–38 yrs (mean 20.5 yrs) and 33
were male (table 1). Seven patients stayed in the centre during
the first period, 42 during the second period and 27 during
both periods. Patients were housed in separate rooms, but
dining and living facilities were shared. Patients infected with
Burkholderia cepacia complex are not admitted to the rehabilita-
tion centre. Patients were mostly referred from one of the
seven Belgian CF centres, but also some were from German
and French centres.
From 1992, infection control measures were instigated to
reduce cross-infection from the environment, i.e. decontamina-
tion of the sinks in each patient room, patient segregation
during physiotherapy according to P. aeruginosa colonisation
and exclusion of patients harbouring B. cepacia complex from
the centre. Nevertheless, P. aeruginosa-colonised patients
continued to share the same physiotherapy room, each patient
using his/her own nebuliser and physiotherapeutic devices,
which were decontaminated separately after each session.
Sampling
Sputum samples were taken from all patients at least on arrival
and departure, and were collected at the end of a physiothera-
peutic session to ensure that the samples originated from the
deeper airways. Environmental samples (10 mL) were taken
during the study period from sink drains of the bedrooms and
the recreation rooms. Some patients were sampled .20 times
during the study period.
Microbiology
Sputum samples were inoculated onto McConkey agar (BBL
Becton Dickinson, Cockeysville, MD, USA). After 2 days of
incubation at 37 C˚, different-looking lactose-negative colonies
were picked, subcultured on 5% sheep blood agar (BBL Becton
Dickinson) and tested for oxidase. Only oxidase-positive
colonies were further investigated, using tRNA-PCR [21].
Genotyping
For each patient, all P. aeruginosa isolates exhibiting different
colonial morphology on McConkey agar were genotyped by
arbitrarily primed PCR, using alkaline cell lysis for DNA
extraction [22], and randomly amplified polymorphic DNA
analysis (RAPD) Ready-to-Go beads (Amersham Biosciences
AB, Uppsala, Sweden) and primer ERIC2 (AAGTAAGTG-
ACTGGGGTGAGCG) at an annealing temperature of 35 C˚, as
described previously [23]. This enabled the number of isolates
that were subsequently genotyped by the more laborious
fluorescent amplified fragment length polymorphism (fAFLP)
method to be reduced, since only single representatives of each
RAPD type were genotyped using this procedure.
Total bacterial DNA was isolated from fresh cultures on
Tryptic Soy Agar using the QIAamp DNA Mini Kit (Qiagen,
Hilden, Germany). fAFLP was carried out as described below.
A combined restriction-ligation procedure was used, in which
10 ng of total genomic DNA was incubated with 2 pmol of
EcoRI adapter, 20 pmol of MseI adapter, 1 U of EcoRI
(Amersham Biosciences), 1 U of MseI (New England Biolabs,
Beverly, MA, USA), 50 mM NaCl, 50 ng bovine serum albumin
per mL (Roche, Basel, Switzerland) and 4 U of T4 DNA ligase
(Amersham Biosciences), in a total volume of 10 mL of
16reaction buffer for 3 h at 37 C˚, after which the mixture
was diluted 20 times with Tris-buffer (Tris 10 mM, EDTA
0.1 mM, pH 8.0). For the selective amplification of the
restriction fragments, 5 mL of the diluted restriction-ligation
mixture was used for amplification in a volume of 10 mL under
the following conditions: 0.4 mM 6-tetrachlorofluorescein-
labelled EcoRI+0 primer, 1.2 mM MseI+C primer (E1;
Eurogentec, Seraing, Belgium), 0.2 mM deoxynucleoside
triphosphate, 1.5 mM MgCl2, 16reaction buffer and 1 U of
GoldStarTM DNA polymerase (Eurogentec). After 2 min of
incubation at 72 C˚ and at 94 C˚, the cycling conditions were 36
cycles of 30 s at 94 C˚, 30 s at 65–56 C˚ and 60 s at 72 C˚. During
the first 13 cycles, the annealing temperature was lowered by
0.7 C˚ per cycle. After an additional 10-min incubation at 72 C˚,
the samples were cooled. An overview of PCR primers and
adapter sequences is shown in table 2.
A combination of 12 mL deionised formamide, and 0.3 mL GS-
400 high-density size standard and 0.2 mL GS-500 size standard
(which both contain ROX-labelled fragments in the range of
50–500 bp) were added to each 1 mL of PCR product. This
mixture was then electrophoresed on an ABI PRISM 310
(Applied Biosystems, Foster City, CA, USA).
A similarity matrix was calculated using the BaseHopper
programme [21], and from this a similarity tree was con-
structed by neighbour joining, using the programme PHYLIP
[24]. Fingerprints that were clustered to .90% similarity were
visually checked to enable final decisions with regard to
similarity. Visual checking of fingerprints that were assessed
by the software as having ,90% similarity showed that such
fingerprints always differed from each other by at least three
major peaks. Visual interpretation of fingerprints assessed by
the software as having ,90% similarity led, in some cases, to
the conclusion that the fingerprint was identical. Therefore, a
final decision with regard to clonality of isolates possessing
fingerprints with o90% similarity, according to the software,
was based on human interpretation.
Statistical analysis
Data are presented as mean¡SD or median (interquartile range
or SEM). Statistical analysis of the epidemiological data was
carried out using the unpaired t-test when groups were
normally distributed and the Mann-Whitney rank-sum test
when the normality test failed. A 95% confidence interval for
the difference in median time in the centre between the group
with a possible patient-to-patient transmission and the group
without transmission was obtained using a bootstrapping
procedure [25].
RESULTS
A total of 749 P. aeruginosa isolates from 76 patients for which
the colony morphology on McConkey agar was different were
genotyped by arbitrarily primed PCR (RAPD). For each
patient, at least one representative of each different RAPD
type was further genotyped by fAFLP, enabling digital
comparison of the genomic fingerprints. Figures 1 and 2
represent some of the fAFLP-fingerprints obtained, with
figure 2 representing details of three different fAFLP finger-
prints in a superimposed manner.
Only 71 different P. aeruginosa genotypes were found among
the 749 isolates, indicating that, in individual patients, isolates
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with different colonial morphology mostly belonged to the
same genotype. Fifty-seven of these genotypes were only
found in a single patient (distinct genotypes), while 14 were
found in more than one patient (cluster genotypes). More than
half of the patients (49) carried only one genotype, 20 carried
two genotypes and seven carried three genotypes.
Thirty-two patients (42%) were colonised by one or more
strains with distinct genotypes, 32 patients (42%) had one or
more genotypes belonging to at least one cluster, and 12
patients (16%) carried both distinct and cluster strains.
Of the 44 patients with cluster strains, 36 carried strains that
belonged to only one cluster and eight had strains belonging to
two clusters. There was a statistical difference between the age
TABLE 1 Clinical characteristics of the patients
Patient
No.
Age
yrs
Sex Colonised
since
Stay duration
days (periods)
FVC
%
FEV1
%
Cluster
type
1 15 M 1992 14 127 137 Z and Y
2 17 F 1984 18 100 63 Z
3 15 F 1996 144 107 100 Y
4 15 M 1991 48 (2) 95 89 Y
5 19 F 1998 89 (2) 134 112 Y
6 13 F 1991 236 (2) 86 76 Y
7 26 M 1992 98 (2) 41 25 Y
8 21 F 1996 25 77 50 Y
9 5 F NA 38 NT NT Y
10 25 M ,2001 178 (4) 69 32 Y and R
11 7 F 2000 115 45 38 Y
12 10 F ,1999 68 (3) 73 51 X
13 16 F ,2000 84 (3) 69 51 X
14 18 F ,1994 253 (3) 83 65 W
15 8 F NA 86 (3) 105 83 W
16 21 M ,1999 430 (3) 52 23 U
17 26 F ,1999 213 (4) 48 18 U
18 17 F ,1997 39 (3) 70 37 U
19 26 M ,1997 78 (2) 107 82 U and P
20 31 M 1998 31 NA NA U
21 19 M 1992 84 46 31 T
22 8 M ,2001 160 (6) NT NT T
23 9 M 1996 391 (7) NA NA T
24 15 F 1991 25 88 48 T
25 30 M ,1991 41 (2) 53 22 R
26 30 M ,1998 276 48 16 Q
27 18 F 1993 94 (4) 72 48 Q and M
28 16 F 1994 39 (2) 102 100 Q
29 13 M 1996 56 (2) 92 95 P and O
30 27 M ,2000 65 (2) 62 36 P
31 27 M ,2000 122 (3) 35 14 P
32 21 F ,2000 41 (2) 55 41 P and M
33 14 F NA 102 (2) 116 99 P and O
34 22 F 1985 35 34 22 O
35 26 F 1983 79 (2) 74 47 O and M
36 23 F ,1999 11 103 47 O
37 18 M ,1999 104 (4) 96 85 O
38 18 F ,2000 546 (3) 83 60 O
39 16 M ,1999 211 (2) 71 54 J
40 13 F ,1999 285 (5) 62 46 J
41 33 M ,1990 44 44 22 M
42 28 F 1977 38 63 29 M
43 20 F ,2001 45 (2) 73 76 K
44 15 F ,2001 42 (2) 100 84 K
45 22 F 1991 49 49 25
46 18 F ,2000 89 (4) 76 49
47 34 F ,1999 59 (2) 65 34
48 20 F ,2000 37 40 25
49 16 F ,1993 321 (3) 52 36
50 22 M ,1996 37 (2) 62 35
51 37 F ,1989 27 89 56
52 22 F 1995 44 104 85
53 32 M 1993 456 47 28
54 20 M ,1999 158 (2) 51 35
55 33 M 1984 28 83 57
Patient
No.
Age
yrs
Sex Colonised
since
Stay duration
days (periods)
FVC
%
FEV1
%
Cluster
type
56 12 F 1989 35 67 48
57 27 F 1993 62 (2) 67 48
58 15 M 1993 25 82 70
59 29 F NA 59 56 22
60 21 M 1998 36 32 20
61 26 M 1993 84 (2) 30 21
62 22 M NA 31 43 21
63 28 M ,1990 81 (2) 47 23
64 26 M ,2000 111 (2) 46 21
65 23 F 1990 21 96 75
66 22 M 1992 56 (2) 93 48
67 10 M ,2000 85 (4) 126 115
68 12 F NA 28 65 48
69 34 F 1985 49 (2) 85 62
70 26 M ,1988 35 27 17
71 26 F 1984 59 (2) 42 24
72 14 M ,2000 79 (2) 100 27
73 5 M NA 204 (2) 64 65
74 18 F NA 23 103 96
75 23 F 1991 64 (2) 53 25
76 19 F 1982 17 46 49
FVC: forced vital capacity; FEV1: forced expiratory volume in one second; M:
male; F: female; NA: data not available; NT: not tested because of young age or
mental retardation.
TABLE 1 (Continued)
TABLE 2 Adapter and primer sequences used for
fluorescent amplified fragment length
polymorphism-based genotyping
Adapters and primers Sequence
EcoRI adapter1 59 CTCGTAGACTGCGTACC
EcoRI adapter2 59 AATTGGTACGCAGTCTAC
MseI adapter1 59 GACGATGAGTCCTGAG
MseI adapter1 59 TACTCAGGACTCATC
EcoRI+0 primer 59 (tet)GACTGCGTACCAATTC
MseI+C primer 59 GATGAGTCCTGAGTAAC
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of the patients with cluster strains (19¡6.95 yrs (1.05)) versus
the age of patients with distinct strains (22.3¡7.49 yrs (1.32),
p50.04). The patients with a cluster strain had similar lung
function test results when compared with those with distinct
strains (FEV1: 49.0% (31.5–82.5) versus 35.5% (24.5–56.5),
p50.092; FVC: 76.5¡25.7 (4.1) versus 65.3¡24.8% (4.4),
p50.065).
The 32 patients who had distinct genotypes had a median
number of genotypes of 1.3, while the patients with strains
belonging to one or more clusters carried a median number of
1.6 genotypes per patient (NS). The 32 patients with distinct
genotypes had a median stay duration in the institute of 177
days, i.e. during the study period and in the past, while the 44
patients with shared genotypes had a median stay in the
institute of 197 days (NS). During the study period, the two
groups had a similar duration of stay (group of patients with
distinct genotype 52.5 days (35–84) versus 81.5 days (40–152) in
the group with cluster genotypes, p50.092).
Among the 44 patients with cluster genotypes, there was one
group of 10 patients (including one sibling pair) with the same
genotype, one group of seven patients, one of six, two of five,
one of four, one of three and six groups of two patients
(including two sibling pairs). All three pairs of siblings shared
at least one genotype with their sibling. Of the 44 cluster
patients, 38 had a shared genotype already on arrival.
The median stay during the study of the 68 patients who
definitely did not acquire P. aeruginosa from another patient
during their stay was 60.5 days. Eight patients acquired a new
genotype during their stay. The eight patients with new
acquisition of a cluster type during the study period (10.5%)
had a median stay of 132 days (NS). The null hypothesis of no
difference in length of stay between both groups cannot be
formally rejected at the 5% significance level. To quantify the
size of the difference, a 95% confidence interval was estimated
for the difference in median stay between both groups with a
bootstrap procedure. This confidence interval was equal to
-14,192.5 and is rather wide, but lies largely above 0, indicating
a longer stay for the group with possible patient-to-patient
transmission.
One patient underwent two episodes of possible patient-to-
patient transmission (with two different cluster types), during
both study periods. For at least five of these eight patients, the
newly acquired genotype, for which a strain with the same
genotype was present in another patient during the stay, was
transient, since it could no longer be isolated from the patients’
sample taken on departure (table 3). Of these eight newly
infected patients, three at most were persistently colonised
with the newly acquired strain (4%). One patient continued to
carry the newly acquired strain 1 yr later, as determined from
a nasopharyngeal aspirate taken after lung transplantation. In
the other two patients, the newly acquired strain was cultured
just before leaving the rehabilitation centre and, unfortunately,
no further samples could be obtained thereafter. The patient-
to-patient transmission took place twice in the first period and
seven times in the second (and longest) study period.
Only four P. aeruginosa isolates could be cultured from 13
environmental sampling sites: one from a bedroom sink and
three from the recreation rooms. However, these isolates
belonged to distinct genotypes and were also different from
the patients’ genotypes.
DISCUSSION
Debate continues as to whether regular stay in a CF
rehabilitation centre is beneficial to CF patients. Benefits
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FIGURE 1. Fluorescent amplified fragment length polymorphism fingerprints
of Pseudomonas aeruginosa isolates from different patients, illustrating different
genotypes: a–c) three different patients belonging to cluster Y; d) one patient
belonging to cluster U; e, f) two siblings belonging to cluster J.
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FIGURE 2. Fluorescent amplified fragment length polymorphism fingerprints
belonging to three different clusters (––: cluster Y; ??????: cluster U; ----: cluster J)
(only fragments between 60 and 120 bp shown).
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include opportunity for sport, and intensified and optimised
physiotherapeutic techniques. More attention is paid to
feeding habits, and the social and psychological benefits of
peer contact are obvious. However, some reports have
indicated the opportunities for cross-infection of important
CF pathogens, in particular P. aeruginosa and B. cepacia complex
species. The aim of this study was to assess the risk of
transmission of P. aeruginosa in the Belgian rehabilitation
centre in De Haan. In Belgium, most CF patients are seen on a
regular basis in one of seven hospital reference centres and are
sporadically referred to the rehabilitation centre in De Haan,
where adult patients live together in a home for several weeks,
with separate bedrooms but with shared living and dining
facilities. Younger patients live together as in a boarding
school. From 1992, segregation has been practiced. Patients are
cohorted in a P. aeruginosa-negative or a P. aeruginosa-positive
group during physiotherapeutic sessions and, since 1995, the
sinks and water closets are decontaminated daily by alter-
natively rinsing with vinegar and liquid bleach.
The risk and frequency of P. aeruginosa cross-infection among
CF patients remains controversial. Genotyping techniques,
such as macro-restriction analysis in combination with pulsed-
field gel electrophoresis, RAPD and fAFLP have enabled
reasonably accurate determination of the clonal relationship of
P. aeruginosa isolates from patients within a CF centre or region
[26–29].
Nevertheless, different conclusions on the transmissibility of
this pathogen have been drawn from two recent molecular
epidemiological studies from two large centres without
segregation policies in Australia [16] and Canada [20]. The
Australian cross-sectional study found a widespread clone of
P. aeruginosa in 55% of 118 infected patients in a paediatric CF
clinic [16]. In contrast, the Canadian longitudinal study, run
over two decades, showed a low risk of patient-to-patient
spread among 174 patients, except for patients with prolonged
and close contacts, such as siblings [20]. Previous studies have
supported the position of both groups, and indicate the
difficulty of making general statements about this highly
diverse and adaptable pathogen. Cross-sectional and longi-
tudinal studies in Liverpool [12, 14], Manchester [13, 30, 31]
and Sheffield [32] have provided compelling evidence for
transmission of highly transmissible strains. In a Norwegian
CF centre, 45% of the patients colonised with P. aeruginosa
carried the same strain [15]; these patients had previous
contacts at summer camps and training courses. This once
more raised the issue of the risk of cross-infection associated
with CF holiday camps. OYENIYI et al. [33] previously
demonstrated that the five P. aeruginosa-negative patients
who attended a winter camp in Spain together with 17 patients
who were already colonised with P. aeruginosa all acquired P.
aeruginosa strains identical to those carried by the colonised
patients. The findings of HOOGKAMP–KORSTANJE et al. [34] were
completely different. Ninety-one CF patients who attended a
CF camp had respiratory cultures performed on arrival, after 2
weeks, after 2 months and regularly thereafter. The incidence
of cross-infection was 7% in previously P. aeruginosa-negative
individuals. The incidence of new and persistent P. aeruginosa
colonisations was ,2%. The authors concluded that the overall
risk of acquisition was comparable to that occurring in the
community, and that it was trivial compared with the obvious
joy and social benefit derived from a holiday camp. A Brazilian
study [35] in an outpatient CF clinic also concluded that the
risk of cross-infection is low.
In this study, the genotypic diversity of P. aeruginosa isolates
was identified initially by RAPD analysis and then with fAFLP
in the case of representative isolates of different RAPD types
cultured from individual patients. By including multiple
isolates from individual patients, the findings of a previous
report [26], which concluded that the discriminatory power of
RAPD and fAFLP were similar, was confirmed. In all cases
studied here, isolates with identical RAPD fingerprints also
TABLE 3 Numbers of patients with shared genotypes and number of possible patient-to-patient transmissions during the study
period
Genotype
designation
Patients with
this genotype n
Patients with this
genotype on arrival n
Patients with shared
genotypes with overlapping stay n
Possible patient-to-patient
transmission during stay
K 2 (1 S) 2 0 0
M 5 5 0 0
J 2 (1 S) 2 0 0
O 7 5 2 2 T
P 6 5 1 1 P or T
Q 3 2 1 1 P or T
R 2 1 1 1 T
T 4 4 0 0
U 5 3 5 1 P
W 2 0 2 2 T
X 2 2 0 0
Y 10 (1 S) 9 0 1 T
Z 2 2 0 0
S: sibling pair; P: permanent, i.e. the same genotype acquired during the stay was still present on departure; T: transient, i.e. the same genotype could not be isolated
from the patient upon departure.
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had identical fAFLP fingerprints, ensuring that no unrelated
isolates were grouped into the same RAPD genotype. For each
patient, all of the RAPD products were obtained during the
same thermal cycling and electrophoresis run, to avoid
differences due to the limited reproducibility of the technique.
fAFLP is generally known to be more reproducible and, due to
automated digitisation of the fingerprints, it makes large-scale
comparison of hundreds of fingerprints possible, an endeavour
that is impossible with RAPD analysis. This combined use of a
rapid and cheap initial screening technique (RAPD) and a
more sophisticated, reproducible and digitised, but also more
expensive and laborious technique (fAFLP), enabled the
authors to genotype a large number of isolates in an affordable,
reasonably convenient, and a highly reliable and discrimina-
tory manner. Moreover, the established library of fAFLP
fingerprints of CF P. aeruginosa strains can be used for further
comparisons and long-term studies.
To the authors’ knowledge, this is the first study to examine
the risk of cross-infection in a CF rehabilitation centre, where
patients live together closely and for long periods of time.
Among the 749 P. aeruginosa isolates examined, which
deliberately included different colony morphology types from
an individual patient, only 71 different genotypes were found.
In most chronically colonised patients, different colony
morphology types were observed on the primary isolation
plate, but in most cases these belonged to the same genotype.
HOOGKAMP-KORSTANJE et al. [34] also observed that isolates
dissimilar in macroscopic appearance and of different ser-
otype, pyocin type and phage type, could be of the same,
unique genotype. This conclusion was supported by DA SILVA
FILHO et al. [35].
Forty-nine of the 76 patients (64%) carried only a single
genotype, 20 carried two genotypes (26%) and seven carried
three types (10%). This confirms the data by
MAHENTHIRALINGAM et al. [27], who reported that 15 out of 20
patients were colonised by a single strain and that five out of
20 were colonised with two or more strains. This was also in
agreement with the findings of HOOGKAMP-KORSTANJE et al.
[34].
All three sibling pairs in the present study harboured at least
one strain in common. These findings are also supported by
the data of SPEERT et al. [17], who found that 10 out of 12 sibling
pairs carried the same strain. GROTHUES et al. [36] stated that
cross-infection between siblings is common and showed that in
three out of the five cases where only one sibling harboured
P. aeruginosa, the siblings lived in separate homes.
Of the 44 patients that carried a strain that was also present in
other patients, 38 already carried this strain on arrival at the CF
centre. Therefore, the strain could have been acquired from a
common source or from another patient during one of the
previous stays in the CF centre, before more stringent infection
control measures were introduced. For example, when
considering the Y cluster, nine out of ten patients were already
colonised with the same strain at the beginning of the study
period. Although the 10th patient could have newly acquired
his Y-cluster strain (since it could not be cultured from the
sample taken at arrival), this strain was isolated sporadically
and intermittently from five of the 36 isolates, taken from 16
samples of this patient over a period of 8 months. It is possible
that this patient carried the Y-cluster strain at arrival, but only
in low numbers. Eight out of the 10 patients with genotype Y
isolates attended the centre before the study period and these
previous stays overlapped for at least 53 and, at most, 242
days, with a total of 1,583 days of overlap. Therefore, cross-
infection could have occurred in this centre during previous
stays. However, two children carrying this cluster strain had
never stayed in the rehabilitation centre before. It is possible
that they acquired this strain at their own CF centres through
contacts with other Y-cluster patients.
During the study period, nine episodes in eight patients were
noted in which the patient was newly infected by a genotype
already carried by another patient during overlapping stay. In
such cases it is difficult to avoid the conclusion that patient-to-
patient transmission occurred.
The role of the environment as a source of P. aeruginosa
acquisition in CF-patients is difficult to prove and remains a
matter of debate. Most previous studies [16, 37–39] have not
been able to identify P. aeruginosa in hospital wards or have
found only a small number of isolates, which were different
from the CF strains. However, DO¨RING et al. [40] linked several
strains from hospital sinks to those carried by patients in
sputum, on their hands, throat, nose and anus, and on the
hands of staff members. Due to the stringent antiseptic
measures, the presence of P. aeruginosa in environmental
samples at the centre in this study centre may be low. In
addition, genotyping showed that those isolates were distinct
from those found in patients.
For most patients carrying isolates with the same genotype, it
is difficult to assess whether this is due to direct patient-to-
patient transmission, to a persistent source of infection in the
environment or to continuous recontamination of the environ-
ment by colonised patients, which increases the risk of
infection from an environmental source. In the De Haan
centre, the environment seemed an unlikely source, because
the few P. aeruginosa environmental isolates that were cultured
were different from patient isolates. Furthermore, the large
genotypic diversity that one can expect among environmental
P. aeruginosa isolates would not predict the occurrence of
several patients with identical isolates when these isolates
had been acquired independently from the environment.
Therefore, it seems likely that an important reservoir respon-
sible for P. aeruginosa acquisition is the infected CF patient, a
hypothesis strengthened by the high number of identical
strains found in sibling studies, including this report.
In summary, these findings confirm that different colonial
morphotypes of Pseudomonas aeruginosa from the same cystic
fibrosis patient usually belonged to the same genotype. Since
38 out of the 44 patients with shared genotypes already carried
their genotype on arrival, patient-to-patient transmission could
have happened in the past, during previous stays. The risk of
patient-to-patient-transmission during the study period (with a
total stay of 8,218 days) was relatively low (10%), and the risk
of persisting colonisation with a newly acquired strain during
the study period was also low (4%). The influence of strain-
specific differences in Pseudomonas aeruginosa transmissibility,
infection control practices or acquisition from environmental
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reservoirs (natural or contaminated) on the data collected in
this study remains unclear. However, it seems reasonable to
conclude that each of these factors should be taken into
account in debating the controversy that surrounds the
prevalence, management and risks of Pseudomonas aeruginosa
cross-infection.
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 ii. Article 2: Survey of Pseudomonas aeruginosa genotypes in Belgian 
colonised Cystic Fibrosis patients. 
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ABSTRACT 
To examine whether patients shared genotypes and to compare the genotypes of the isolates 
from the same patients during two subsequent years, we set up a Belgian databank of P. 
aeruginosa genotypes of all colonised CF-patients.  
Sputum samples from a total of 276 P. aeruginosa colonised patients were sent during 2003 
and from a subgroup of 95 patients in 2004. Patients were asked for social contact between 
each other by questionnaire. All P. aeruginosa isolates exhibiting different colonial 
morphology on McConkey agar were first genotyped by arbitrarily primed PCR, whereafter 
single representatives of each RAPD-type were further genotyped by fAFLP-analysis.  
For the 213 patients from whom P. aeruginosa could be cultured and 910 isolates, a total of 
163 genotypes were found. 75% of patients harboured only one genotype. In most of the 
limited number of clusters, previous contacts could be suspected. The same P. aeruginosa 
genotype was recovered from 80% of the patients, studied during both years.  
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We concluded that most patients harbour only one P. aeruginosa genotype, despite different 
colonial morphotypes. There is only a limited number of clusters, and most patients seem to 
have the same genotype during both years.  
 
INTRODUCTION 
Pseudomonas aeruginosa, widely spread in soils and water, has been the leading pathogen in 
cystic fibrosis (CF) lung pathology during the last three decades [1-3]. The means by which 
this organism is acquired are not yet fully elucidated. After initial infection, chronic infection 
and colonisation - as defined by the criteria of Döring et al. [4] - causes destruction of lung 
tissue and reduction of lung function, and finally leads to early death. According to the U.S. 
CF Foundation database of 1996 the median survival of P. aeruginosa colonised CF-patients 
was 28 years, while the median survival for non-colonised patients was 39 years [5]. Kerem et 
al.  [6] demonstrated that patients, colonised with P. aeruginosa at the age of 7 years, had a 
mean FEV1 (Forced Expiratory Volume in one second) that was 10% lower than that of non-
colonised patients.  
Currently, some CF-centres report the spread of highly transmissible strains that are multi-
resistant and, in some patients, are responsible for primary infection [7-12]. Other studies, 
however, do not find evidence of clonal spread [13-16]. 
 In Belgium the total number of CF patients, registered in the Belgian registry in 2003 [17], 
was 843, of whom 750 are followed at the 7 CF centres and 280 are considered as colonised 
by P. aeruginosa, according to the criteria of Döring et al. [4]. 
 With this study we prospectively set up a Belgian databank of P. aeruginosa genotypes, 
isolated from colonised CF-patients to examine whether patients shared genotypes. In 
addition we wanted to compare the genotypes of the isolates from the same patients during 
two subsequent years.  
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METHODS 
Patients 
The 7 Belgian CF-centres, Sint Vincentius Hospital/University Hospital Antwerp, HUDERF- 
Erasme Hospital (ULB) Brussels, University Hospital of the Free University of Brussels (AZ-
VUB), University Hospital Ghent, University Hospital Leuven, University Hospital Liège,  
and Hospital of the Catholic University of Louvain-la Neuve (UCL), participated in this 
study.  
Samples from a total of 276 Pseudomonas aeruginosa colonised CF patients, were sent to the 
microbiology laboratory of the University Hospital of Ghent during 2003. 
Sputum samples were mostly collected during an out-patient consultation, at the end of a 
physiotherapeutic session to ensure that the samples originated from the deeper airways; when 
patients were too young or unable to expectorate, a nasopharyngeal aspirate or swab was 
taken (26 nasopharyngeal samples vs. 250 sputum samples). All centres were asked to send 
another sputum sample one year later. For a subgroup of 95 patients, this sputum sample was 
obtained. 
Patients were aged from 5 to 54 years (with a mean age of 24.2 years ± 8.8 SD).  
Patients had to sign an informed consent and approval of the ethics committee of the 
University Hospital of Ghent was obtained for this national multi-centre study. 
Patients filled in a questionnaire (addendum 1 and 2), assessing the frequency and intensity of  
 
 current and previous social contacts with other CF patients. CF sibling contacts were not  
 
taken into account. Scores arbitrarily assigned to the different possible answers in the  
 
questionnaire were agreed among the CF specialists involved in the  
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study, whereby a subjective weight was given to the type of contact (for example an  
 
intimate relationship was scored as the highest risk factor for transmission  
 
(score 10) and occasional social contact as a minor risk factor (score 4)). 
 
 Ninety-three percent of patients, from whom sputum P. aeruginosa was cultured, completed  
 
the questionnaire.  
 
Segregation policies are installed in all CF centres, except for one centre. In the outpatient 
clinics, P. aeruginosa colonised patients and non-colonised patients are seen on different 
days. Care givers are strongly advised not to wear jewellery and to wash hands and 
stethoscopes between each visit. The patients are asked to wash hands before lung function 
measurement and to produce a sputum sample in a separate room. Filters of the lung function 
equipment are always changed  between patients. Patients with CF are always hospitalised in 
a single room and contact with other hospitalised CF patients are strongly discouraged. 
These recommendations date from the mid nineties and most centres implemented them in the 
following years.   
 
 
Microbiology 
Sputum samples were inoculated onto McConkey agar (BBL Becton Dickinson, Cockeysville, 
Md.). After two days of incubation at 37°C, differently looking lactose negative colonies were 
picked, subcultured on 5% sheep blood agar (BBL) and tested for oxidase. Only oxidase 
positive colonies were further identified, using tDRNA-PCR [18].  
Genotyping  
For each patient, all P. aeruginosa isolates exhibiting different colonial morphology on 
McConkey were first genotyped by arbitrarily primed PCR, using alkaline cell lysis for DNA-
extraction and Randomly Amplified Polymorphic DNA-fingerprinting analysis (RAPD) 
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Ready-to-Go beads (Amersham Biosciences AB, Uppsala, Sweden) and primer ERIC2 
(AAGTAAGTGACTGGGGTGAGCG) at an annealing temperature of 35°C, as described 
previously (18). This enabled us to reduce the number of isolates that were subsequently 
genotyped by the more laborious fluorescent amplified fragment length polymorphism 
analysis (fAFLP), since only single representatives of each RAPD-type were further 
genotyped by this procedure. The AFLP-technique is described earlier [19]. 
 
Statistical analysis 
Values of the inter patient contact score as obtained from the questionnaires did not 
approach the normal distribution (Kolmogorov-Smirnov Z-statistic p < 0.001), therefore all 
analysis involving questionnaire scores were done under the nonparametric assumption. In 
order to assess putative differences in number of inter-patient contacts between patients with a 
unique P. aeruginosa genotype compared to patients who share at least one Pseudomonas 
genotype with at least one unrelated patient, median inter patient contact scores were 
calculated for both groups and compared with the Median test. Dispersion of score values 
around a median value is presented as interquartile (p25  p75) ranges. Differences in the 
distributions of score values between two groups were assessed with the Mann-Whitney U 
test for two independent samples. Strength of association was expressed as (crude) odds ratios 
(OR) with 95% confidence intervals (95% CI) to the estimated OR. For any reported measure, 
statistical significance was accepted, if the two-tailed probability level was <0.05. All 
analyses were performed with the statistical software package SPSS v. 12.0 (Chicago, 
Illinois).  
 
RESULTS 
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P. aeruginosa isolates of a total of 213 out of 276 P. aeruginosa colonized patients were 
genotyped using AFLP-analysis. For 63 patients no P. aeruginosa could be isolated, because 
culture remained negative (n = 10), because technical problems occurred (n = 29) or because 
another gram negative organism was cultured (n = 24: 6 patients harboured Achromobacter 
xylosoxidans instead of P. aeruginosa, 15 patients harboured Stenotrophomonas maltophilia, 
one patient harboured both and 2 patients were colonised with Burkholderia cepacia). 
A total of 910 P. aeruginosa isolates were genotyped using RAPD-analysis.  
After excluding isolates from the same patient with an identical RAPD-pattern, 272 isolates 
from the patients together with an additional 3 reference strains (i.e. epidemic strains from the 
UK: the Liverpool, Manchester and Midlands strain, kindly provided by Prof. T. Pitt (Public 
Health Laboratory Services, London, UK) were typed with fAFLP, a technique which is more 
reproducible than RAPD-analysis and which yields digitized fingerprints allowing large 
numbers of fingerprints to be compared by computer. 
 
For the 213 patients and 910 isolates, a total of 163 genotypes were found, based on AFLP-
analysis. The majority of patients (160) had one genotype, 48 patients had 2 genotypes and 5 
patients had 3 genotypes (Fig1).  
 
A limited number of clusters, i.e. 13, with cluster defined as a group of patients carrying P. 
aeruginosa isolates with the same genotype, was observed. There were three additional 
sibling clusters. The sizes of the clusters and the centre origins are listed in Table 1.  
 
Sixty-six patients (sibling clusters excluded), i.e. 30 %, carried a P. aeruginosa isolate with a 
shared genotype. Five (2.3 %) of them were part of two clusters.  
There were six 2-person clusters, one cluster of 4 patients, one of 5 patients, two of 9, two of 
10 and one of 12 patients. 
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Eleven of the 13 non sibling clusters contained patients of multiple centres. In 10 out of 11 
multi-centre clusters, former contact between patients could be established, such as stay in a 
rehabilitation centre (rehabilitation centre A (rehab A) and rehabilitation centre B (rehab B)), 
attendance to a CF-camp and/or social contact.  
When comparing the inter patient contact score between cluster patients and non-cluster 
patients, there was a significant difference between both groups (100% of the cluster patients 
filled in their questionnaire versus 90% of the non-cluster patients) (Fig 2). Although mean 
age of both groups was comparable (24.7 ± 9.1 for the non cluster patients versus 23.2 ± 8.2 
years for the cluster group), the cluster patient group (n = 66) reported on average a 
significantly higher inter patient contact score compared to the non-cluster group (n = 132) 
(rank-sum p < 0.001), i.e. a median inter patient contact score 9.0 (inter-quartile range 5.0 to 
14.0) was observed with patients sharing a P. aeruginosa genotype with at least one other 
(unrelated) patient versus a median score of 4.0 (inter-quartile range 0 to 7.0) among patients 
with a unique P. aeruginosa fingerprint (p < 0.001).  
During 2003, siblings (n = 24) invariably presented with at least one similar P. aeruginosa 
genotype at the level of the sibling pair (n = 12). Siblings represented 4.5% of the non-cluster 
group of patients (6/132) compared to 27.3% of the cluster group of patients (18/66) (p < 
0.001), indicating that siblings are actually much more prone to be involved in the spread of 
P. aeruginosa among CF patients (odds ratio = 7.9, 95% CI = 3.0 to 21.0, p < 0.001). 
 The latter observation might be explained by differential inter-patient contact rates,  
considering that sibling patients (n=24) tended to report on average a higher number of inter-
patient contacts compared to unrelated patients (n=174) with median inter-patient contact 
score values of 5.0 (interquartile range 4.0 to 14.0) and of 4.0 (interquartile range 0.0 to 9.0), 
respectively, a difference that was marginally significant (p=0.051) within the limits of our 
sample size.    
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Although inter patient contact scores of siblings may actually be correlated data at the sibling 
pair level, numbers of colonized siblings were too low in our survey to assess and account for 
such a correlation and therefore score values of all patients were handled as independent 
observations. To ascertain however, that a potential interaction at the sibling pair level did not 
bias our primary results in comparing the score values of the cluster and non-cluster groups of 
patients, the analysis was also repeated by including only a single value for each sibling pair 
(a single mean score for each sibling pair, the lowest value of each sibling pair, and the 
highest value of each sibling pair, respectively) but these analyses did not alter our results.  
  
None of the Belgian P. aeruginosa genotypes matched with the 3 UK strains. 
 
For a total of 95 patients, sputum samples were collected from two subsequent years (2003 
and 2004) and genotyped by AFLP (see fig.3). In total, the same genotype could be recovered 
from 76 patients (80%) in both years. 
We compared the genotypes that were newly acquired in 2004 with the genotypes already 
present in the patients centre in 2003. None of the new genotypes accorded with the known 
centre genotypes, except for 1 patient, whose novel genotype appeared to be identical to a 
genotype recovered from his sibling in 2003.  
 
DISCUSSION 
This study is, to our knowledge, the first to compare the P. aeruginosa genotypes of most 
colonised CF patients within one country. Most studies examine the variety of genotypes 
within a centre [12, 14, 20, 21, 22, 23] and do not reflect the national situation. 
The only comparable study was carried out in the UK  [24], where a national survey was set 
up to identify and characterize transmissible P. aeruginosa strains in CF patients in England 
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and Wales and for which isolates were requested from over 120 hospitals and a sample size of 
approximately 20% of the CF population in each centre was attempted, but not always 
reached. 
 
Different PCR fingerprinting techniques have been developed and different names have been 
used for identical techniques. Terms such as amplification fragment length polymorphism 
(AFLP), arbitrarily primed PCR (AP-PCR), DNA amplification fingerprinting or random 
amplification of polymorphic DNA (RAPD) are often used indiscriminately and create a  
Tower of Babel phenomenon. In a letter to the editor in the Journal of Clinical Microbiology 
in 2003 several CF physicians and microbiologists therefore emphasized the need for 
harmonization of techniques  and technique designations for genotyping clinical isolates of P. 
aeruginosa from CF patients [25]. Most of the epidemiological research studies [12, 16, 23] 
were based on Pulsed Field Gel Electrophoresis (PFGE).  
Since our laboratory had already built up experience to genotype other species with RAPD 
and fAFLP [19], we chose to use these techniques. This choice was supported by a 
publication of Speijer et al. [26], which showed that AFLP analysis was comparable with 
PFGE and RAPD analysis for P. aeruginosa isolates. DAgata et al. [27] also confirmed these 
findings. 
 
 Theoretically, it can be imagined that strains with slightly different fingerprints have acquired 
only recently mutations which make them differ from each other. As such they may be 
clonally related, whereas the different fingerprints suggest otherwise. The opposite can be true 
as well: strains with identical fingerprints can in reality differ from each other, because not all 
genomic differences are revealed by the fingerprint, which is obtained by looking at only 
some regions of the genome. When obvious differences exist in parts of the genome that are 
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not addressed by the technique, these will be overlooked and the technique will yield identical 
fingerprints for genotypically different strains. 
Therefore, it can be stated that genotyping studies are an approximation of the true genetic 
relatedness among the strains studied. But, whether cross infection is underestimated due to 
the fact that strains with slightly different fingerprints belong to the same genotype anyway is 
difficult to say, since overestimation on the other hand is possible as well, as a consequence of 
genotypically different strains with coincidentally identical fingerprints. 
However, the study of Speijer et al. [26], as discussed above, showed that the clustering 
obtained with three different genotyping techniques (RAPD, AFLP and PFGE), which address 
different regions of the genome, was concordant, and given the fact that we also found 
concordance between AFLP and RAPD in this and our previous study [19], we assume that 
the obtained discrimination reflects the true occurrence of genotypes and that there is neither 
under- nor overestimation of cross infection. 
 
For the 213 patients and 910 isolates tested , a total of 163 genotypes were found, indicating 
that different morphotypes in one patient often have the same genotype. 
This conclusion is supported by Hoogkamp-Korstanje et al.  [28] and Da Silva Filho et al . 
[20]. Our previous study [19] in a CF rehabilitation centre also showed that for 76 patients 
only 71 different P. aeruginosa genotypes were found among 749 isolates, indicating that in 
individual patients isolates with different colonial morphology mostly belonged to the same 
genotype.  
In this national study 75% of the colonized patients carried only one genotype, during 2003. 
This confirms the data by Mahenthiralingam et al. [29] and by our previous study [19] where 
more than half of the patients (49 out of 76 patients) carried only one genotype, 20 carried 
two genotypes and seven carried three genotypes. 
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For 24 out of 279 patients, thought to be colonized by P. aeruginosa, another gram negative 
organism was identified.  
Some of the isolates, identified genotypically as A. xylosoxidans or S. maltophilia, seemed to 
be considered initially as atypical P. aeruginosa in the routine laboratory. Due to the diversity 
of colonial morphologies and biochemical reactivity encountered, misdiagnosis of gram 
negative non-fermenters cultured from CF sputum may occur. In one study, misidentification 
of 11% of A. xylosoxidans strains was reported [30]. 
In our previous report about the occurrence of two large clusters of A. xylosoxidans in a CF 
rehabilitation centre population, the routine hospital laboratory initially also misidentified this 
organism as P. aeruginosa [31]. 
 
There was only a limited number of clusters (n = 13 + 3 sibling clusters) and a limited number 
of patients harbouring one of these P. aeruginosa cluster genotypes. 
These findings were similar to the data of the Vancouver CF-centre [16], and of the Brazilian 
study of Da Silva Filho et al. [20]. 
Other centres however reported large clusters with the same genotype. A paediatric CF centre 
in Victoria, Australia [12] showed that 55% of the 118 P. aeruginosa colonized CF children 
carried the same genotype and the Manchester CF centre [9] had to deal with a multi-resistant 
strain carried by 14% of its 154 P. aeruginosa colonised patients. In the Liverpool CF centre 
[8] 60% of 92 P. aeruginosa colonised children harboured the same strain. 
A Norwegian study [11] showed that only 7/60 patients had a distinct genotype, one large 
main cluster of 27 patients (45%) and remaining clusters of 2 to 4 patients. Patients were 
known to have contact during holiday camps and training courses. 
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In the nationwide survey of Scott and Pitt [24], 72% of patients harboured strains with unique 
genotypes, which matches with our results. In their study small clusters of related strains were 
evident in some centres, presumably indicating limited transmission of local strains. The most 
prevalent strain (Liverpool genotype) accounted for 11% of patient isolates from 15 of the 
31 examined centres. The second most prevalent strain (Midlands1) was recovered from 86 
patients in nine centres and clone C (originally described in Germany) was found in 15 
patients from 8 centres. A fourth genotype, identical to the Manchester strain, was found in 
three centres. 
The Liverpool, Manchester and Midlands strain were not detected in the Belgian CF 
population. Our data did not point to a Belgian problem genotype, carried by many patients, 
since the largest cluster containing 12 patients (5.5% of the studied population). 
We are not aware whether these cluster genotypes are multi-resistant, since susceptibility 
testing was not performed during this study. 
 
In our study most clusters, i.e. 11 out of 13, contained patients from different CF centres. The 
vast majority of these patients had spent time in one of the two Belgian rehabilitation centres 
(rehab A and rehab B), or had participated in a CF camp and at least 2 patients had even 
shared a hospital room with another non sibling CF patient in the past. 
For instance, the largest cluster of 12 patients (cluster 4) contained 6 patients who had stayed  
several years ago in rehabilitation centre B and 4 patients who had stayed in rehabilitation 
centre A, whereby the remaining two patients were siblings that had stayed in both centres 
(for prolonged periods). One could speculate that this sibling pair caused the spread of this  
cluster genotype. In cluster 6, eight out of the 10 patients previously stayed in rehabilitation  
 
centre A. The clustering of the isolates from the remaining 2 patients remains  
 
unexplained, since they never stayed there, and since they mentioned close contacts only with  
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each other, but not with others from cluster 6. 
 
In cluster 8, three of the 5 patients went on a CF holiday camp (the majority of them however 
could not specify which camp and how long, since these camps took place more than 10 years 
ago).  
One 2-person cluster (cluster 13) contained 2 young school children, followed at the same CF  
centre: these girls were close friends, and, though they were discouraged to do so, they always  
came together to the centre, with the same car. They went to the same physiotherapist,  
shared the same classroom and even wanted to be hospitalised at the same moments. In these  
two children obviously patient-to-patient transmission had occurred (within the setting of an 
in- ánd outpatient CF clinic). 
 
Since segregation between P. aeruginosa colonised and non colonised patients has been 
installed in almost all Belgian CF centres (except for centre B) and rehabilitation centres since 
the mid-nineties, patient-to-patient transmission is suspected to have occurred before that 
period.  
In our previous study in one of the two Belgian rehabilitation centres [19], during 2002 and 
2003, 38 of the 45 patients with a cluster strain already carried this strain upon arrival at the 
CF-centre. Therefore, we could not exclude that acquisition of this strain from a common 
source, or from another patient, occurred during one of the previous stays in the CF-centre, 
before more stringent infection control measures were introduced. 
That study could establish that the risk of patient-to-patient-transmission during the study 
period was relatively low (10%), and that the risk of persisting colonisation with a newly 
acquired strain during the study period was still lower (4%). 
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In this study siblings carried the same genotype. We did not take into account the sibling 
clusters, nor did we ask for sibling contacts in the questionnaire, since it could be considered 
as obvious for siblings to share genotypes [13, 32, 33].  
In this Belgian cohort study siblings (total n = 24) represented 4.5% of the non-cluster group 
of patients (6/132) compared to 27.3% of the cluster group of patients (18/66) (p < 0.001) 
indicating that siblings are actually much more prone to be involved in the spread of P. 
aeruginosa among CF patients (odds ratio = 7.9, 95% CI = 3.0 to 21.0, p < 0.001).  
We could speculate that siblings stay in a rehabilitation centre more often than non siblings, 
because the burden of having 2 children with CF (and having to spent a lot of time to their 
treatment) forces the parents to send their children to these centres from time to time. 
It is also possible that siblings are more willing to stay in a rehabilitation centre or to attend a 
holiday camp, since they dont have to go alone (in contrast with the non sibling patients). 
 
For a subgroup of 95 patients, genotyping was performed for two subsequent years. The vast 
majority continues to carry its own predominant strain (80%). Of those who had a new 
genotype in 2004, only one patient had a genotype that matched with a genotype from his own 
centre in 2003. The strain with the matching genotype however had been isolated from his 
sister in 2003. Therefore, we could speculate that this strain was already present in the patient 
during 2003, but had been overlooked, or that it had been newly acquired from his sister in the 
period between both samplings. Since no other new genotypes in 2004 seemed to match 
with the known centre genotypes of 2003, we could state that patient-to-patient transmission 
probably did not occur within the Belgian centres for this subgroup of patients. 
 
A limitation of the study is the lack of validation of the questionnaire. As mentioned in  
 
Methods the scores were arbitrarily assigned, since no other scoring system, evaluating the  
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amount and intensity of social contacts has been used in CF studies. 
 
 Although this scoring system remains subjective this questionnaire enabled us to  
 
assign to some degree an inter patient contact score to each patient. 
 
 In summary, our findings confirm that, in the Belgian CF population, different colonial 
morphotypes of P. aeruginosa from the same CF patient usually belong to the same genotype. 
We could also state that genotypic diversity among P. aeruginosa strains is large in Belgian 
CF patients. We could describe only a limited number of clusters. The situation is different 
from one country to another and depends probably on multiple factors such as number of 
patients per centre, presence of highly transmissible strains, segregation measures. Most 
clusters in our study could probably be explained by previous social contacts (mostly during 
previous stays in rehabilitation centres and during holiday camps). Eighty percent of a 
subgroup of patients continued to carry its own predominant strain during 2 subsequent years, 
suggesting a small genotype variability in the same patient despite the large genotype 
diversity in this survey.  
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Table 1. P. aeruginosa genotypes shared in Belgian CF patients 
 
Centre  Number of  
patients 
A B C D E F G H 
Cluster 1 2  1  1     
Cluster 2 2    1b    1 
Cluster 3 4   1 1 1  1  
Cluster 4 12    2x2Sc 6b   2 
Cluster 5 2     2    
Cluster 6 10 2b   2S+1c 3   2 
Cluster 7 2    1b 1    
Cluster 8 5  1  1 3    
Cluster 9 10  2   2x2S+2c  2Sc  
Cluster 10 9  3b   2 1 1 2S 
Cluster 11 2    1    1 
Cluster 12 9 2 1  2S+1c 1  2Sc  
Cluster 13 2    2     
 
Legend: 
a Centres A and H form one CF centre on different locations in the same city. 
 
b The P. aeruginosa strains of one or more of these patients are part of two clusters. 
 
c 2S: two siblings or one sibling pair, 2x2S: two sibling pairs, 2S+1: one sibling pair and one  
 
unrelated patient. 
104
Fig 1. Flow chart of the study design and of the genotyping 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 2. Score of inter patient contacts among patients with a unique P. aeruginosa genotype 
(non-cluster group) compared to that of patients sharing a P. aeruginosa genotype with at 
least one other unrelated patient (cluster group) 
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Fig 3. Comparison of genotypes of 95 patients, sampled during both 2003 and 
2004
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Addendum 1 
Questionnaire for parents of CF patients younger than 14 years 
1. Does your child have contact with other CF patients in the family, other than brothers 
or sisters (now or in the past)?                                                                           YES/ NO  
      If yes, with whom?(initials only)                                           YES = score 8 
2. Does your child have contact with other CF patients in the classroom (now or in the 
past)?                                                                                                                  YES/ NO  
      If yes, with whom?(initials only)                                           YES = score 7 
3. Does your child have contact with other CF patients at school (now or in the past)?          
                                                                                                                                YES/ NO                         
   If yes, with whom?(initials only)                                              YES = score 4  
4. Did your child ever stay in a rehabilitation centre?                                           YES/ NO 
   If yes, in which rehabilitation centre and for how long?              YES = score 5 
5. Did your child ever attend a CF camp?                                                             YES/ NO 
   If yes, which camp and for how long?     YES = score 5 
6. Has your child ever shared a hospital room with another CF patient (brothers and   
   sisters excluded)?                                                                                                YES/ NO 
   If yes, with whom?(initials only)                                             YES = score 5 
7. Does your child have social contacts with other CF patients (excluding contacts 
already asked for in previous questions)?                                                        YES/ NO   
    If yes, with whom?(initials only)                                            YES = score 4 
 
                                                                                          TOTAL SCORE= 
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Remark 1: social contacts are physical contacts (playing, talking etc.), not written or 
internet contacts! 
Remark 2: you are not obliged to answer these questions, if you dont want to. 
Remark 3: this questionnaire is sent to the investigating lab, under closed envelop. 
The members of your CF-centre will not be able to look at the answers. 
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Addendum 2.  
Questionnaire for adolescents and adults with CF 
1. Do you have contact with other CF patients in the family, other than brothers or sisters   
   (now or in the past)?                                                                                             YES/ NO  
   If yes, with whom?(initials only)                                              YES = score 8 
2.  Do you have contact with other CF patients in the classroom (now or in the past)?  
                                                                                                                                 YES/ NO            
    If yes, with whom?(initials only)                                             YES = score 7 
3.  Do you have contact with other CF patients at school or at work (now or in the past)?          
                                                                          YES/ NO                          
   If yes, with whom?(initials only)                                YES = score 4  
4.  Did you ever had a sexual relationship with another CF patient?              YES/NO 
   If yes, with whom?(initials only)                              YES = score 10  
5.  Did you ever stay in a rehabilitation centre?                              YES/ NO 
   If yes, in which rehabilitation centre and for how long? YES = score 5 
6.  Did you ever attend a CF camp?                                                                      YES/ NO 
   If yes, which camp and for how long?..YES = score 5 
7.  Have you ever shared a hospital room with another CF patient (brothers and sisters  
   excluded)? If yes, with whom?(initials only)                            YES/ NO  
                                                                                                                        YES = score 5 
8. Do you have social contacts with other CF patients (excluding contacts already asked    
   for in previous questions)?                                              YES/ NO     
   If yes, with whom?(initials only)                              YES = score 4 
                                                                                       TOTAL SCORE = 
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Remark 1: social contacts are physical contacts (talking, going out together etc.), not 
written or internet contacts! 
Remark 2: you are not obliged to answer these questions, if you dont want to. 
Remark 3: this questionnaire is sent to the investigating lab, under closed envelop. 
   The members of your CF-centre will not be able to look at the answers. 
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c. Transmissibility and clinical impact of A. xylosoxidans. 
Although colonization of CF patients with A. xylosoxidans is well-established, 
epidemiological studies thus far could not establish much transmission of strains of this 
species. Dunne and Maisch [121] reported already in 1995 persistent colonization of 
outpatients with A. xylosoxidans, but did rule out patient-to-patient transmission by means 
of PCR-based genotyping. Vu-Thien et al. [85] found persistent colonization of patients 
with B. cepacia, S. maltophilia and A. xylosoxidans, but could show the presence of 
identical isolates in different patients only for B. cepacia. In a large study, including 92 A. 
xylosoxidans positive patients from 46 centres, Krzewinski et al.[86] found five pairs of 
patients with genotypically identical A. xylosoxidans isolates, of which two pairs of 
siblings and one pair of friends. Furthermore, one additional case of cross-colonization 
with A. xylosoxidans in two siblings was reported [122], persistent airway colonization 
with A. xylosoxidans in two brothers with cystic fibrosis and the presence of the same 
strain in two of eight colonized children [123]. Recently, Hansen et al. [124]  published 
a study, which showed that 8 of their 16 patients chronically infected with A. xylosoxidans 
harboured a common strain. These findings confirm our data. 
 
Because several authors have indicated that transmissibility of A. xylosoxidans is low (with 
small clusters of maximum 2 patients), we studied the transmissibility of this species among 
residents of a CF rehabilitation centre. 
 
 iii. Article 3: Shared genotypes of Achromobacter xylosoxidans strains 
isolated from patients at a cystic fibrosis rehabilitation centre. 
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During a study examining transmission of Pseudomonas aeruginosa among 76 cystic fibrosis patients in a
rehabilitation center, where patients stay in close contact during prolonged periods, several clusters of patients
carrying genotypically identical P. aeruginosa, as well as two clusters of 4 and 10 patients, respectively,
colonized with genotypically identical Achromobacter xylosoxidans strains, were discovered.
Clonal spread of Pseudomonas aeruginosa strains has re-
cently been reported in United Kingdom and Australian cystic
fibrosis (CF) centers (1, 5, 11, 16). This seems to be an emerg-
ing infection control problem in CF centers, necessitating the
segregation of P. aeruginosa colonized and noncolonized pa-
tients. A large longitudinal study in British Columbia, Canada,
however, did not identify P. aeruginosa patient-to-patient
transmission in that CF population (21).
Therefore we started a study to determine the prevalence
and risk of transmission of P. aeruginosa among cystic fibrosis
patients in a Belgian rehabilitation center (24). The P. aerugi-
nosa-colonized patients lived there together as in a boarding
school, with shared dining and living facilities but with separate
bedrooms.
During this study we also identified other nonfermenting
gram-negative bacilli present together with P. aeruginosa. Pre-
dominant among these were Achromobacter xylosoxidans iso-
lates. Moreover, using randomly amplified polymorphic DNA
analysis and amplified fragment length polymorphism (AFLP)
typing, we found that several patients were carrying a common
genotype of A. xylosoxidans.
The taxonomic position of A. xylosoxidans has been uncer-
tain during the last decades, leading to name changes from
Achromobacter to Alcaligenes and back to Achromobacter. The
species was described as the type species of the genus Achro-
mobacter (27). Later on, Kersters and De Ley (13) proposed to
transfer the type species of the genus Achromobacter to the
genus Alcaligenes. However, more recently, the results of phy-
logenetic analyses of 16S rRNA nucleotide sequences and a
difference of more than 10% in GC content of DNA demon-
strated that Achromobacter xylosoxidans and Alcaligenes faeca-
lis, the type species of the genus Alcaligenes, belong to two
distinct genera, respectively, Achromobacter and Alcaligenes
(26).
Isolation and identification. Lactose-negative colonies on
McConkey agar were isolated on Mueller-Hinton agar contain-
ing 5% sheep blood and subsequently tested for oxidase activ-
ity. Oxidase-positive isolates were further identified using
tDNA-PCR in combination with fluorescent capillary electro-
phoresis (2). This approach enables us to distinguish between
gram-negative nonfermenters such as P. aeruginosa, Burkhold-
eria species, and Achromobacter species (unpublished data) by
comparing the tDNA-PCR fingerprints of unknowns with
those of reference strains in a library (available at http://allserv
.ugent.be/mvaneech/LBR.html). Identification of isolates as
Achromobacter xylosoxidans was confirmed by using API20 NE
(bioMe´rieux, Marcy l’Etoile, France). Some of the isolates,
identified genotypically as A. xylosoxidans, were initially con-
sidered atypical P. aeruginosa in our routine laboratory. Due to
the diversity of colonial morphologies and biochemical reac-
tivity encountered, misdiagnosis of gram-negative nonferment-
ers cultured from CF sputum may occur. In one study, mis-
identification of 11% of A. xylosoxidans strains was reported
(20).
Genotyping. For each patient, the A. xylosoxidans isolates
were first genotyped by means of arbitrarily primed PCR, using
alkaline cell lysis for DNA extraction and randomly amplified
polymorphic DNA analysis with Ready-to-Go beads (Amer-
sham Biosciences AB, Uppsala, Sweden) with primer ERIC2
(AAGTAAGTGACTGGGGTGAGCG) at an annealing tem-
perature of 35°C, as described previously (9). For the purpose
of selective restriction fragment amplification (AFLP), total
bacterial DNA was isolated from fresh cultures on tryptic soy
agar by using a QIAamp DNA Mini kit (QIAGEN, Hilden,
Germany). AFLP with one fluorescent primer (fAFLP) and
with fragment length analysis by means of ABI310 (Applied
Biosystems, Foster City, Calif.)-based capillary electrophoresis
was carried out basically as described previously (22). Briefly,
a combined restriction-ligation procedure was used in which 10
ng of total genomic DNA was incubated with 2 pmol of EcoRI
adapter, 20 pmol of MseI adapter, 1 U of EcoRI (Amersham
Biosciences), 1 U of MseI (New England Biolabs, Beverly,
Mass.), 50 mM NaCl, 50 ng of bovine serum albumin per l
(Roche, Basel, Switzerland), and 4 U of T4 DNA ligase (Am-
ersham Biosciences) in a total volume of 10 l of 1 reaction
buffer for 3 h at 37°C, after which the mixture was diluted 20
times with Tris buffer (Tris [10 mM]–EDTA [0.1 mM], pH 8.0).
* Corresponding author. Mailing address: Department of Pediatric
Pulmonology, University Hospital Ghent, De Pintelaan 185, B9000
Ghent, Belgium. Phone: 32 9 240 35 81. Fax: 32 9 240 38 61. E-mail:
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For the selective amplification of the restriction fragments, five
microliters of the diluted restriction-ligation mixture was used
for amplification in a volume of 10 l under the following
conditions: 0.4 M TET-labeled EcoR  0 primer, 1.2 M
Mse  C primer (Eurogentec, Seraing, Belgium) (E1), 0.2 mM
each deoxynucleoside triphosphate, 1.5 mM MgCl2, 1 reac-
tion buffer, and 1 U of GoldStar DNA polymerase (Eurogen-
tec). After 2 min of incubation at 72°C and at 94°C the cycling
conditions were 36 cycles of 30 s at 94°C, 30 s at 65 to 56°C, and
60 s at 72°C. During the first 13 cycles, the annealing temper-
ature was lowered by 0.7°C per cycle. After an additional 10
min of incubation at 72°C, the samples were cooled. An over-
view of PCR primers and adapter sequences is shown in Table
1. To one l of PCR product were added 12 l of deionized
formamide and 0.3 l of GS-400 High Density size standard
and 0.2 l of GS-500 size standard, which both contain ROX-
labeled fragments in the range of 50 to 500 bp, and this mixture
was electrophoresed on an ABI PRISM 310 system (Applied
Biosystems, Foster City, Calif.).
A total of 102 A. xylosoxidans isolates were cultured from the
sputa of a total of 13 patients out of a population of 76 patients
studied (Table 2). The sputum cultures of the remaining 63
patients were negative for A. xylosoxidans. Only four genotypes
were established on the basis of fAFLP genotyping. Two ge-
notypes, designated S and V, were found in 4 and 10 patients,
respectively, with 1 patient carrying both genotypes. Therefore,
we designated these patients S1 to S3 (patients carrying only
genotype S), B (the patient carrying both genotypes), and V1
to V9 (patients carrying only genotype V). Two patients, S3
and B, each had a separate A. xylosoxidans genotype in addi-
tion to their cluster strains. These genotypes were designated
“S3 other” and “B other.” Patients V6 and V7 were siblings,
carrying not only the same A. xylosoxidans genotype V but also
identical P. aeruginosa genotypes (J). For both siblings, the P.
aeruginosa genotype (J) was already present at arrival, but the
shared A. xylosoxidans was acquired after an interval of 6
months (Table 3 and Table 4). Another two patients (V4 and
V5), with a common A. xylosoxidans genotype (V), also had a
P. aeruginosa genotype (Y) in common. Only one of the two
patients carried the Y genotype at arrival.
Patients B and V2 also shared the same P. aeruginosa geno-
type (U). Patient V2 already carried this genotype at arrival; B
acquired it during the fourth month of their overlapping stay.
In a previous report (24) we showed that the majority of shared
TABLE 1. Adapter and primer sequences used for
fAFLP-based genotyping
Adapter or primer Sequence
EcoI adapter 1 .................................5 CTCGTAGACTGCGTACC
EcoI adapter 2 .................................5 AATTGGTACGCAGTCTAC
MseI adapter 1.................................5 GACGATGAGTCCTGAG
MseI adapter 2.................................5 TACTCAGGACTCATC
EcoRI  0 primer ...........................5 (tet)GACTGCGTACCAATTC
MseI  C primer.............................5 GATGAGTCCTGAGTAAC
TABLE 2. Patients and the different genotypes of P. aeruginosa and A. xylosoxidans isolates
Patient Total no. ofisolates
Total no. of
genotypesa
No. of isolates of indicated genotype
A. xylosoxidans P. aeruginosa
S V Other J I O Q R T U Y Other
S1 5 1/0 5
S2 2 1/0 2
S3 36 2/1 25 2b 9
B 32 3/3 1 1 14c 2 1, 13
V1 30 1/1 4 26
V2 63 1/1 24 39
V3 11 1/1 3 8
V4 13 1/1 4 9
V5 37 1/3 7 1 5 24
V6 61 1/1 2 59
V7 28 1/1 1 27
V8 16 1/1 6 10
V9 15 1/3 1 8 2, 4
a Number of different A. xylosoxidans/P. aeruginosa genotypes for this patient.
b Designation of the additional A. xylosoxidans genotype of patient S3 is “S3 other.”
c Designation of the additional A. xylosoxidans genotype of patient B is “B other.”
TABLE 3. Times during study period 1 in which patients stayed at
the rehabilitation center
Patient
Patient stay occurred duringa:
January February March April
Wks 1
and 2
Wks 3
and 4
Wks 1
and 2
Wks 3
and 4
Wks 1
and 2
Wks 3
and 4
Wks 1
and 2
Wks 3
and 4
V1
V2 VU VU VU VU VU VU VU
V3
V4
V5 Y
V6 J J J J J J J JV
V7 J J J J J J J J
V8
V9
B U
S1
S2 S S
S3 S S S S S
a Underlining represents the time periods during which patients stayed at the
rehabilitation center. Capital letters represent shared genotypes of A. xylosoxi-
dans (S, V) and P. aeruginosa (J, U, Y).
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P. aeruginosa genotypes were already cultured at arrival, so
patient-to-patient transmission seemed to have happened
mostly in the past, before segregation was introduced (since
1992) and before infection control practices such as daily de-
contamination of the sinks and water closets by alternatively
rinsing with vinegar and liquid bleach (since 1995).
The 10 V-cluster patients came from seven different CF
centers. During the first study period (from 8 January 2001
until 30 April 2001) (Table 3), 7 of these patients had an
overlapping stay: in only one patient (V2) the V genotype was
already cultured at arrival and in one patient (V6) a “new
infection” could be suspected, and the five other patients re-
mained free of the V genotype during this period. In the
second study period (from 1 September 2001 until 23 October
2002) (Table 4), three patients (V2, V4, and V8) already car-
ried the V genotype at (re)admission. However, possibly new
infections with the V genotype could be suspected for six
patients (V1, V3, V5, V7, V9, and B), all occurring within a
period of 6 months (between 1 October 2001 and 1 April
2002).
Three of the four S-genotype patients were followed at the
same CF center (B, S1, and S2). The S genotype was already
cultured at arrival in three patients (S1, S2, and S3). The fourth
patient (B) only showed his S genotype at readmission, after an
absence of 3 months. During the previous stays of this pa-
tient—lasting 4 and 2 months, respectively—cultures were al-
ways negative for the S genotype. It is therefore possible that
patient-to-patient transmission took place at the CF center,
where the patient was followed with two other S-cluster pa-
tients.
All patients colonized with A. xylosoxidans, except patients
S1 and S2, also carried P. aeruginosa genotypes, with patient B
having up to three different P. aeruginosa genotypes in addition
to his/her three A. xylosoxidans genotypes. These data at first
glance appear to point to a strong tendency of cocolonization
with P. aeruginosa and A. xylosoxidans but may be biased, since
the study included only patients assumed to be colonized with
P. aeruginosa. No study was undertaken to establish in how
many cases patients were carrying A. xylosoxidans without P.
aeruginosa. Also, Tan et al. (23) reported that most patients
carrying A. xylosoxidans were colonized by P. aeruginosa, and in
another study, six of the eight patients with A. xylosoxidans
were also colonized with P. aeruginosa (17).
We found, for the same population, 14 clusters of P. aerugi-
nosa, comprising 2 to 10 patients per cluster (24). Thus, the
largest cluster of A. xylosoxidans colonization (10 patients) was
the same size as the largest P. aeruginosa cluster. Furthermore,
when a patient was colonized by A. xylosoxidans, its isolates
always belonged to one of two shared genotypes, with patient
B even colonized by isolates of both genotypes, whereas in the
same population 45/76 patients (59%) were found carrying a P.
aeruginosa strain not related to any other strain and thus with
a separate genotype. So it can be stated that there was much
less genotypic diversity among the A. xylosoxidans strains ob-
served compared with the P. aeruginosa strains for the same
patient population.
A. xylosoxidans has been recognized as an emerging CF
pathogen since one study published in 1985 (14) and later on in
several others (3, 4, 6, 7, 8). Fabbri et al. (7) identified 12 of the
71 isolates (16.9%) from 24 patients as A. xylosoxidans. Ferroni
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et al. (8) reported A. xylosoxidans to be the second most fre-
quent gram-negative nonfermenter, after P. aeruginosa, among
1,093 isolates from 148 patients (10 isolates from 8 patients).
Moissenet et al. (17) reported colonization with A. xylosoxidans
in 6% of 120 CF children, with a mean age of 14.2 years for
colonized children. Still, the prevalence may be higher, since in
one study A. xylosoxidans was detected in CF patients only
after usage of a selective medium (18). A phase III study of
aerosolized tobramycin showed that a much higher number of
the 595 patients were colonized with Stenotrophomonas malto-
philia, A. xylosoxidans, Aspergillus species, and oxacillin-resis-
tant Staphylococcus aureus than had been established by the
CF foundation patient registry efforts (4). In this study, A.
xylosoxidans (in 8.7% of the patients) was almost as frequently
isolated as S. maltophilia (10.3%).
Although colonization of CF patients with A. xylosoxidans is
well established, epidemiological studies thus far have been
unable to establish evidence of much transmission of strains of
this species. Dunne and Maisch (6) in 1995 had already re-
ported persistent colonization of outpatients with A. xylosoxi-
dans but did rule out patient-to-patient transmission by means
of PCR-based genotyping. Vu-Thien et al. (25) found persis-
tent colonization of patients with Burkholderia cepacia, S. mal-
tophilia, and A. xylosoxidans but could show the presence of
identical isolates in different patients only for B. cepacia. In a
large study including 92 A. xylosoxidans-positive patients from
46 centers, Krzewinski et al. (15) found five pairs of patients,
which included two pairs of siblings and one pair of friends,
with genotypically identical A. xylosoxidans isolates. Further-
more, one additional instance of cross-colonization with A.
xylosoxidans in two siblings (19) and the presence of the same
strain in two of eight colonized children (17) were reported.
Our study revealed two large clusters of patients colonized by
the same A. xylosoxidans strains. These findings are supported
by a recent publication of Kanellopoulou et al. (12) that
showed that A. xylosoxidans isolates of five colonized CF pa-
tients were genetically related, suggesting a common-source
outbreak.
Although for most of the nonfermenting gram-negative rods
the disk diffusion antibiogram is not validated by the CLSI
(formerly NCCLS), we carried out an antibiogram to evaluate
its possible usefulness as a preliminary typing technique. Sev-
eral interpretation problems were apparent, such as heteroge-
neous growth in the inhibition zone and unclear inhibition
zone borders. In our hands this approach indicated that all
isolates except one showed large inhibition zones for pipera-
cillin (30 to 45 mm) and showed no inhibition zone for ami-
kacin, gentamicin, ofloxacin, ampicillin, aztreonam, temocillin,
cefuroxime, and cefotaxime. The activity of ceftazidime and
meropenem was very variable, while that of cotrimoxazole and
colimycin was difficult to interpret. Fabbri et al. (7) found this
organism to be the least susceptible for antibiotics among
gram-negative nonfermenting rods and concluded that cefta-
zidime was most active. We found very variable results for
ceftazidime, while for only one strain (B other) no large inhi-
bition zone for piperacillin was observed. Also, Saiman et al.
(20) found piperacillin among the most active antibiotics in
vitro. There were no consistent susceptibility characteristics
which enabled one to differentiate between the four genotypes,
but the susceptibility pattern, i.e., colimycin resistance and
combined resistance to aminoglycosides and quinolones, was
considered to be helpful in distinguishing this species from P.
aeruginosa.
The pathogenic potential of these newly emerging CF
“pathogens” has been ill studied. One study (10) addressed the
endotoxic potential of eight species of gram-negative organ-
isms, including A. xylosoxidans, and found that, with the excep-
tion of S. maltophilia, lipopolysaccharide extracted from all of
the bacteria upregulated, by various degrees, expression of
each of the proinflammatory cytokines assayed. Given the high
antibiotic resistance observed in this and previous studies and
taking into account that some strains may be transmissible, it
may be advisable to pay attention to the presence of A. xy-
losoxidans in the lungs of cystic fibrosis patients. Tan et al. (23)
showed in their retrospective case-controlled study of 557 CF
patients that the 13 patients that were chronically infected with
A. xylosoxidans did not deteriorate more in clinical or pulmo-
nary function than patients colonized with P. aeruginosa only.
More clinical data will be necessary in the future to resolve the
issue regarding the pathogenicity of A. xylosoxidans in CF pa-
tients.
In summary, although several authors have indicated that
transmissibility of A. xylosoxidans is low, we report the occur-
rence of genotypically identical strains of this species among
two clusters of CF patients attending the same rehabilitation
center.
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Background: Achromobacter xylosoxidans is increasingly cultured in sputum from cystic fibrosis (CF) patients; nevertheless, there are few
published data on the clinical impact of this infection or chronic colonisation.
Methods: Relying on DNA fingerprinting techniques we studied the prevalence of A. xylosoxidans in our CF population. In a retrospective
case control study the clinical status of patients with at least 3 sputum cultures positive for A. xylosoxidans over at least 9 months, at the
moment of the first positive culture and during the period of colonisation were compared to age (±1 year), gender and to Pseudomonas
aeruginosa colonisation controlled CF patients who had never A. xylosoxidans positive sputum cultures.
Results: The prevalence of patients with at least one positive A. xylosoxidans culture was 17.9%. 5.3% of the patients fulfilled the criteria of
our definition of colonisation.
Colonised patients had a median age of 20 years (range 11–27 years) and a mean colonisation period of 1.5 (±0.9) years.
At the moment of the first positive culture we found significantly lower Bhalla scores on HRCT scans of the lungs (11±3 versus 16±3,
p<0.002), lower Brasfield chest X-ray scores (14±3 versus 18±3, p<0.019), lower FVC values (70%±22 versus 94%±12, p<0.017) and
lower FEV1 values (55%±32 versus 78%±23, p=0.123), although the latter did not reach significance. There was no significant difference
in body mass index (BMI) (18.7±3 kg/m2 versus 19.6±3 kg/m2, p=0.8).
Over the study period A. xylosoxidans-colonised patients did have more need for intravenous antibiotic treatment courses (19 versus 5,
p<0.001); nevertheless, there was no significant difference in lung function decline over the study period (FVC: −6.25±12.34% versus
−5.62±8.30%, p 0.77, FEV1: −5.62±8.30% versus −1.87±11.58%, p<0.47).
Conclusions: The prevalence of A. xylosoxidans infection or colonisation is probably underestimated. Colonised patients are mostly older,
with more pronounced lung damage and lower lung function values. Although there was more need for intravenous antibiotic treatment
courses, no faster decline in lung function was observed in A. xylosoxidans positive patients.
© 2006 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Achromobacter xylosoxidans; Pseudomonas aeruginosa; Lung function; Morbidity1. Introduction
Although Pseudomonas aeruginosa is the main Gram-
negative pathogen found in the sputum of cystic fibrosis
(CF) patients, recently other Gram-negative bacilli emerge.
Among these emerging pathogens has been Achromobacter
xylosoxidans. The clinical significance of this micro-⁎ Corresponding author. Tel.: +32 9 2403586; fax: +32 9 2403861.
E-mail address: frans.debaets@ugent.be (F. De Baets).
1569-1993/$ - see front matter © 2006 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2006.05.011
121organism is unclear and there is limited evidence to direct
treatment.
A. xylosoxidans is increasingly cultured in CF sputum;
nevertheless, there are few published data on the clinical
impact of this infection or chronic colonisation.
In a group of 557 CF patients, Tan et al. [1] reported a
prevalence of 2.3%, considering patients with at least three
positive cultures over a period of 6 months. In a prospective
multi-centre German study Steinkamp et al. [2] reported a
prevalence of 1.1% among 1419 CF patients. In the Belgian
CF Register 2002 [3], gathering 826 patients, a prevalence ofJCF-00311; No of Pages 4
ed by Elsevier B.V. All rights reserved.
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ARTICLE IN PRESS1.9% is mentioned, collecting all patients with at least one
positive culture over the year 2002. The U.S. Cystic Fibrosis
Foundation's National Patient Registry, however, reported
over the last 10 years an increase in prevalence of patients
harbouring A. xylosoxidans: 0.5%, 1.9%, 2.7%, 3.8% and
5.2% in 1995, 1996, 1997, 1999 and 2002, respectively [4].
In order to study the relative risk of cross infection of P.
aeruginosa in our CF population DNA fingerprinting
techniques were carried out on multiple Pseudomonas and/
or Gram-negative non-fermenting bacilli.
Relying on these DNA techniques we studied the
prevalence of A. xylosoxidans in our CF population. We
evaluated the clinical history of CF patients with at least 3
positive sputum cultures for A. xylosoxidans over at least
9 months. In a retrospective case control study we evaluated
the clinical status of the patients at the moment of the first
positive culture and during the period of colonisation.
2. Materials and methods
A. xylosoxidans is a motile Gram-negative, oxidase-
positive rod. The morphology of A. xylosoxidans colonies is
not that different from that of P. aeruginosa colonies.
In our CF centre, taking care of 140 CF patients, P.
aeruginosa strains and strains of morphologically different
looking Gram-negative, non-fermenting bacilli were sent to
the DNA laboratory for further identification using DNA
fingerprinting techniques.
2.1. Isolation and identification
Lactose negative colonies on McConkey agar were
isolated on Mueller Hinton Agar containing 5% sheep
blood, and subsequently tested for oxidase activity. Oxidase
positive isolates were further identified using tDNA-PCR in
combination with fluorescent capillary electrophoresis [5].
This approach enables us to distinguish between Gram-
negative non-fermenters like P. aeruginosa, Burkholderia
species and Achromobacter species (unpublished data), by
comparing the tDNA-PCR fingerprints of unknowns with
those of reference strains in a library (available at http://
usersallserv.ugent.be/~mvaneech/LBR.html). Identification
of isolates as A. xylosoxidans was confirmed by using
API20 NE (bioMérieux, Marcy l'Etoile, France).
2.2. Patients
A retrospective case control study design was used. In our
CF centre each patient is seen on a three monthly basis, when
a clinical history is taken, a sputum culture and a lung
function measurement are done. In young children or none
sputum producers, a pharyngeal swab alternating with a
nasopharyngeal aspirate is taken. Patients with at least 3
positive cultures for A. xylosoxidans over at least 9 months
were compared to subjects who had never grown A.
xylosoxidans, matched for age (±1 year), gender and P.122aeruginosa colonisation. Our CF group of 140 patients did
not allow to match each colonized patient with 2 control
patients, unless we enlarged the age limits to ±2 years which
would have weakened our findings because of the large age
range (4 years). Comparison was done for chest X-rays and
high-resolution CT scans, relying on the Brasfield [6] and
Bhalla [7] scores, respectively. Lung function measurements,
forced vital capacity (FVC) and forced expiratory volume in
one second (FEV1) and body mass index (BMI, kg/m
2) were
compared. Over the study period the need for intravenous
antibiotic courses and the decline in lung function were
evaluated.
Data were compared for the period from the first positive
culture for A. xylosoxidans until 31 December 2004, giving a
mean colonisation period of 1.5 (±0.9) years.
Respiratory function tests were performed on a Master-
lab® (Jaeger®).
Respiratory infections in P. aeruginosa colonised patients
are treated for 2–3 weeks with intravenous antibiotics: an
aminoglycoside and a betalactam penicillin. When there was
coexistent A. xylosoxidans infection antibiotics were chosen,
where possible, according to their in vitro activity against
both micro-organisms. Elective three monthly intravenous
antibiotic treatment policy for chronic P. aeruginosa
infection is not practised in our CF clinic. Symptomatic
patients with positive sputum cultures only for A. xylosox-
idans were treated, relying to severity, with two intravenous
antibiotics chosen according to in vitro sensitivity or with an
oral antibiotic (cotrimoxazol or tetracycline) for 2–3 weeks.
Statistical analysis was done using the chi-square test and
the unpaired Student's t-test for normally distributed data.
3. Results
17.9% of our patient population did have at least one
positive culture for A. xylosoxidans.
According to our criteria, the prevalence of A. xylosox-
idans colonisation in our CF-centre was 5.3%. All patients
remained colonised with A. xylosoxidans throughout the
study period.
Eight patients out of 140 at our CF centre were found to
be colonised by A. xylosoxidans. They had a median age of
20 years (range 11–27 years) and a mean colonisation period
of 1.5 (±0.9) years. They were compared to 8 control CF
patients, who have never grown A. xylosoxidans, matched
for age (±1 year), gender and P. aeruginosa colonisation.
Seven patients were co-colonised with P. Aeruginosa,
four by Staphylococcus aureus and Stenotrophomonas
maltophilia was cultured intermittently in 2 patients.
At the moment of the first positive culture we found
significantly lower Bhalla-scores on HRCT scans of the
lungs (11±3 versus 16±3, p<0.002), lower Brasfield chest
X-ray scores (14±3 versus 18±3, p<0.019), lower FVC
values (70±22% versus 94±12%, p<0.017) and lower
FEV1 values (55±32% versus 78±23%, p=0.123), although
the latter did not reach significance. There was no significant
Table 1
Comparison of morphologic and functional parameters at the moment of the
first isolation of A. xylosoxidans (mean±standard deviation)
A. xylosoxidans + A. xylosoxidans − p
BHALLA scores 11±3 16±3 <0.002
Brasfield scores 14±3 18±3 <0.019
FVC (% predicted) 70±22 94±12 <0.017
FEV1 (% predicted) 55±32 78±23 =0.139
BMI (kg/m2) 18.7±3 19.6±3 =0.8
Table 2
The number of IV AB treatment courses and decline in lung function
parameters (mean±standard deviation) over the study period (1.5±
0.9 years)
A. xylosoxidans + A. xylosoxidans − P
IVAB treatment courses 19 5 <.001
Lung function decline
FVC (% predicted) 6.25±12.34 4.5±11.9 =0.77
FEV1 (% predicted) 5.62±8.30 1.87±11.58 =0.47
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p=0.8) (Table 1).
Over the study period, A. xylosoxidans-colonised patients
needed more intravenous antibiotic treatment courses (19
versus 5, p<0.001); nevertheless, there was no significant
difference in lung function decline over the study period
(FVC:−6.25±12.34% versus −5.62±8.30%, p 0.77, FEV1:
−5.62±8.30% versus −1.87±11.58%, p<0.47) (Table 2).
4. Discussion
17.9% of our patient population did have at least one
positive culture for A. xylosoxidans. The prevalence in our
centre was significantly higher than that reported in the
literature [1–4]. However, the prevalence measured in our
population is cumulative and not annual; moreover, because
of an ongoing National Pseudomonas study we relied on
DNA fingerprinting techniques for species identification.
Indeed, some of the isolates, identified genotypically as A.
xylosoxidans, were initially considered as atypical P.
aeruginosa in our routine laboratory, using standard
phenotypic identification. It is well known that, due to the
diversity of colony morphology and biochemical reactivity,
misidentification of Gram-negative non-fermenters cultured
from CF sputum may occur. In one study, misidentification
of 11% of A. xylosoxidans strains was reported [8].
The morphology of Achromobacter colonies is not that
different from the appearance of P. aeruginosa colonies. In
the routine laboratory where specific mediums or DNA
techniques are not available, the true prevalence is probably
underestimated.
The prevalence of A. xylosoxidans colonisation in our CF-
centre was 5.3%.
This is comparable with the findings of Burns et al. [9]
who found as part of the pre-enrolment visits for a study on
the use of the aerosolised tobramycine, over a period of
6 months, a positive culture for A. xylosoxidans on three
different occasions in 7% of the 427 screened patients.
As no consensus definition of colonisation is available,
we are aware that our definition of colonisation is debatable.
At the moment of the first positive culture we found
significantly lower Bhalla scores on HRCT scans of the
lungs, lower Brasfield chest X-ray scores, lower FVC values
and lower FEV1 values, although the latter did not reach
significance. There was no significant difference in BMI.
These findings suggest that particularly patients with more123lung damage are prone to infection or colonisation with A.
xylosoxidans. This could explain the older age at which a
first infection is found.
Tan et al. [1] studied 13 patients colonized with A.
xylosoxidans, with a median age of 17.2 years (range 6.5–
32.8). They were compared to 26 control CF-patients
matched for gender, age (±2 years), body weight (±10%),
FEV1 (±10%) and bacterial colonisation. Over a period of
4 years they did not find either a significant difference in
decrease of lung function parameters, neither significant
differences in the use of antibiotics, inhaled antibiotics or
oral or inhaled corticosteroids.
As in their study patients were matched for FEV1, Tan et
al. [1] did not look for lung function differences;
unfortunately, they neither evaluated HRCT-scan scores,
although discrepancy between lung function measurements
and morphologic damage, evaluated by HRCT scan scores
has been reported [10]. Because they had the opportunity to
study a large group of patients, their study would probably
have been more informative if they had included all age-
matched controls irrespective of their FEV1.
We chose in our case control study not to stratify for lung
function.
This study has the weaknesses of all case control studies.
If one matches the control group for lung function, no
conclusions can be made for this parameter as a possible
determinant for A. xylosoxidans colonisation.
Ideally each colonised patient should be compared with as
many controls, matched for age, gender and P. aeruginosa
colonisation as possible, regardless of their lung function.
This would strengthen the findings concerning the possible
role of lung destruction as a permissive factor for
colonisation and the decline in lung function after
colonisation.
A prospective study would of course be more informa-
tive; however, it is difficult to predict who will remain
culture positive and negative over a certain period, and
therefore, large numbers of patients would be required.
Over the study period, A. xylosoxidans-colonised patients
needed more intravenous antibiotic treatment courses. This
finding is not confirmed by the study of Tan et al. [1]. Since
in their CF centre patients with chronic P. aeruginosa
infection received elective three monthly intravenous
antibiotic treatment courses, differences between both
groups possibly have been attenuated. Whether the higher
need for IV antibiotics, as observed in our study, depends on
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pronounced lung damage remains an unanswered question.
Although there seems to be a tendency, there was no
significant difference in lung function decline over the study
period. Probably such differences may become evident after
a longer follow-up period in a larger group of patients.
Until now, a low transmissibility of A. xylosoxidans was
reported. However, recently we reported [11] that out of 13
patients colonised with A. xylosoxidans, staying in a CF-
revalidation centre, 9 patients shared one genotype, three
shared another genotype and one patient had both genotypes,
suggestive for patient-to-patient spread. Accordingly Kanel-
lopoulou et al. [12] reported 9 colonised patients, 5 of them
sharing the same genotype.
Considering the results of Tan et al. [1], who could not
detect a need for more intravenous antibiotic treatment
courses in A. xylosoxidans-colonised patients and our finding
that colonised patients have more damaged lungs, it is
tempting to hypothesize that A. xylosoxidans is a coloniser of
more damaged lungs rather than a destructive infectious
organism; however, it is obvious that more, especially
prospective, studies on the clinical relevance of A.
xylosoxidans infection or colonisation are warranted.
5. Conclusions
Relying on routine laboratory analysis, the prevalence of
A. xylosoxidans infection or colonisation is probably under-
estimated. Mostly older patients, with more pronounced lung
damage and lower lung function values have positive
cultures. Data on the post-acquisition morbidity showed a
higher need for intravenous antibiotic treatment courses. No
significantly faster decline in lung function was observed in
A. xylosoxidans positive patients; however, observations
were done retrospectively in a small number of patients over
a short period; therefore, one should be cautious interpreting
these results. In view of the possibility of patient to patient
spread further longitudinal studies are warranted to elucidate
the clinical impact of A. xylosoxidans infection in CF
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d. Longitudinal analysis of genotypes per patient 
 
While looking for ‘cluster’ genotypes in the studies conducted, we first had to evaluate 
whether patients harboured  one or more genotypes. 
In the study in De Haan (p. 73) we followed 76 patients. 
From these 76 patients, a total of 749 P. aeruginosa isolates, for which the colony 
morphology on McConkey agar was different, were genotyped by arbitrarily primed PCR 
(RAPD). For each patient, at least one representative of each different RAPD-type was further 
genotyped by fAFLP, enabling digital comparison of the genomic fingerprints. Only 71 
different P. aeruginosa genotypes were found among these 749 isolates, indicating that in 
individual patients isolates with different colonial morphology mostly belonged to the same 
genotype. Fifty-seven of these genotypes were only found in a single patient (distinct 
genotypes), while 14 were found in more than one patient (cluster genotypes). More than half 
of the patients (49) carried only one genotype, 20 carried two genotypes and seven carried 
three genotypes.  
This confirms the data by Mahenthiralingam et al. [103] who reported that 15 out of 20 
patients were colonized by a single strain and that five out of 20 were colonized with two or 
more strains. This was also in agreement with the findings of Hoogkamp-Korstanje et al 
[110]. They observed that isolates dissimilar in colony appearance and of different serotype, 
pyocin type and phage type, could be of the same, unique genotype. This conclusion was also 
supported by Da Silva Filho et al [111].  
 
In the national study (p. 83) we genotyped P. aeruginosa isolates of a total of 213 P.  
 
aeruginosa colonized patients. For the 213 patients and 910 isolates, a total of 163 genotypes 
were found, based on AFLP-analysis. The majority of patients (160) had one genotype, 48 
patients had 2 genotypes and 5 patients had 3 genotypes.  
This indicated again that different morphotypes in one patient often have the same genotype, 
thus confirming the data from the ‘De Haan-study’. 
 
 
 For a subgroup of 95 patients, sputum samples were collected from two subsequent years 
(2003 and 2004) and genotyped by AFLP. Only 6 patients had more than one genotype at one 
occasion, no patients had more than one identical genotype during both years. Of these 6 
samples (on a total of 190 samples, = 95 samples in the 2 consecutive years), 5 contained 2 
genotypes and only one contained 3 genotypes. Seventy-two patients had the same single 
genotype in both years, whereas 17 had a single genotype in both years, differing between 
both years. Of the 5 patients with 2 genotypes at one occasion, 2 had both genotypes of the 
one year different from the one in the other year, whereas 3 had one of both genotypes 
identical to that of the other year. For the patient with 3 genotypes in one year, one of the 3 
was identical to the genotype of the other year (Figure 3). In total, the same genotype could be 
recovered from 76 patients (80%) in both years. In other words the vast majority continues to 
carry its own predominant strain.  
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VIII. Conclusions 
In our research on infection/colonization with gram-negative organisms (P. aeruginosa and A. 
xylosoxidans) in CF patients, we focused on possible patient-to-patient transmission. With 
molecular genotyping techniques we tried to answer the questions presented in the chapter V. 
 
- In our first study in the CF rehabilitation centre Zeepreventorium of De Haan we compared 
the genotypes of the P. aeruginosa carried by colonised patients, during several months 
(publication 1, p. 73) 
 
Question 1. Do the patients, chronically infected by P. aeruginosa carry a ‘unique’ or 
a ‘shared’ genotype?  
Answer: Of the 76 patients observed, 41% were chronically infected by one or more 
strains with distinct genotypes, i.e. with a genotype unrelated to any other genotype 
observed in this population, 43% had one or more genotypes shared with other patients, 
i.e. they carried strains that belonged to a cluster and 16% carried both distinct and cluster 
strains. 
 
Question 2.  Do the patients carry one or more genotypes? 
Answer: 49 out of the 76 patients carried only one genotype, 20/76 carried two genotypes 
and 7 carried three genotypes.  
 
Question 3.   Do the patients acquire a ‘new’ genotype during their stay? 
Answer: During the study period 8 patients acquired a ‘cluster’ genotype. For at least 5 of 
these 8 patients, the newly acquired genotype, for which a strain with the same genotype 
was present in another patient during the stay, was considered as transient, since it could 
no longer be isolated from the patients' sample taken on departure.  
Three patients still harboured this newly acquired strain when they left the centre. 
Unfortunately 2 patients were lost for follow up (one French and one German patient).In 
one patient the same strain was cultured one year later, in BAL-fluid, after lung 
transplantation. In this patient the transmission obviously was persistent. 
So we can conclude that patient-to-patient spread had happened during the study period, though 
infrequently. However, in 58 % of the patients  a cluster genotype could be cultured at 
arrival.This suggests that patient-to-patient transmission could have occurred earlier, and 
on a larger scale, probably before starting segregation measures, in the mid-nineties. 
  
Question 4. Does patients’ genotypes correspond with P. aeruginosa genotypes found 
in the rehabilitation centre environment?    
Answer: Only 4 P. aeruginosa genotypes could be isolated from the 13 environmental 
sources sampled, all belonging to distinct genotypes, different from all the patients' 
genotypes. Thus, infection from the environment seemed unlikely.  
 
- Because of the ongoing debate of the necessity of cohorting patients, chronically 
infected by P. aeruginosa, we set up a national data bank of P. aeruginosa genotypes 
from these CF patients, in collaboration with all 7 Belgian CF centres (publication 2, 
p. 83), to provide answers on the following questions: 
 
Question 5. Do the Belgian CF patients, chronically infected by P. aeruginosa carry a 
‘unique’ or a ‘shared’ genotype?  
Answer: 30% of the patients (sibling clusters excluded) carried a P. aeruginosa strain 
with a shared or cluster genotype. Five (2.3%) of them were part of two clusters.  
 
Question 6. Do the patients carry one or more genotypes? 
Answer: The majority of patients (160/213) had one genotype, 48 patients had 2 
genotypes and 5 patients had 3 genotypes. 
 
Question 7. Do the patients carry the same genotype, when retyped, a year later? 
Answer: Sputum of a subgroup of 95 patients(out of 213), chronically infected with P. 
aeruginosa, was cultured again after one year. The same genotype could be recovered in 
80% of the patients in both years. The other 20% showed at least one different genotype at 
both culture moments. Only one patient showed in the second year a new ' shared' genotype, 
already present in his sibling the year before.
  
 
Question 8. When patients share the same genotype, is there a correlation with the 
amount and intensity of social contact? 
Answer: When comparing the ‘inter patient contact score’ between cluster patients and 
non cluster patients, there was a significant difference between both groups. Although 
mean age of both groups was comparable (24.7 ± 9.1 for the non cluster patients versus 
23.2 ± 8.2 years for the cluster group), the cluster patient group reported on average a 
significantly higher ‘inter patient contact score’ compared to the non-cluster group (rank-
sum p < 0.001), i.e. a median inter patient contact score 9.0 (inter-quartile range 5.0 to 
14.0) was observed with patients sharing a P. aeruginosa genotype with at least one other 
(unrelated) patient versus a median score of 4.0 (inter-quartile range 0 to 7.0) among 
patients with a unique P. aeruginosa fingerprint (p < 0.001).  
 
- During the “De Haan” study we observed frequent co-colonisation with A.  
xylosoxidans . Since there is little knowledge about the transmissibility of this 
organism within CF patients, we wanted to answer the following questions 
(publication 3, p. 113) 
 
Question 9.  Do the patients, chronically infected with P. aeruginosa, who are co-
infected or even co-colonised with A. xylosoxidans carry a ‘unique’ or a ‘shared’ 
genotype of the latter organism?  
Answer: On a total of 13 patients only four genotypes were established based on fAFLP-
genotyping. Two genotypes, designated S and V, were found in four and ten patients 
respectively, with one patient carrying both genotypes. Two patients each had a separate 
A. xylosoxidans genotype in addition to their cluster strains. This indicated that there was 
little genotypic variation and patient-to-patient transmission likely occurred in the past, 
since for a total of  102 isolates of 13 patients only 4 genotypes could be found! 
Recently the group of Hoiby [124] published their data, which showed that 8 of 
their 16 patients chronically infected with A. xylosoxidans harboured a common strain. 
These findings confirm our data. 
 
Question 10. Do the patients carry one or more genotypes of A. xylosoxidans? 
Answer: 10 out of the 13 patients carried one genotype, 3 carried 2 genotypes. 
 
Question 11. Do the patients acquire a ‘new’ genotype of A. xylosoxidans during their 
stay? 
Answer: Six of the 13 patients acquired a cluster genotype of A. xylosoxidans during the 
study period (indicating patient-to-patient transmission during the study period).  
Seven patients already carried their cluster strain at (re)admission. Most of these 7 patients 
had previous stays in the rehabilitation centre or were followed in the same CF centre so, 
for these patients,  patient-to-patient transmission seemed to have happened in the past.  
Previous studies [85, 121] failed to demonstrate such large clustering, but in both studies 
only 8 CF patients with A. xylosoxidans  were considered. Krzewinski et al. [86] however 
included the patients of 69 American CF centres, and ended up with 92 A. xylosoxidans  
positive patients in 46 centres with 5 instances of shared genotypes (2 siblingpairs and 1 
pair of friends). Segregation policy is however not described in this study. 
None of these studies were performed in a rehabilitation centre. Perhaps the close contacts 
in such a “resident” setting have favored the patient-to-patient transmission. Of course this 
study only includes a small amount of  A. xylosoxidans colonized patients, thus 
conclusions should be interpreted carefully. Larger studies are therefore warranted.  
 
 
-The clinical significance of A. xylosoxidans in CF remains unclear and until now, there is 
limited evidence for necessity of treatment. 
Therefore we set up a retrospective case control study to answer the following questions 
(publication 4, p. 120): 
 
Question 12. What is  the prevalence of A. xylosoxidans( = at least one positive 
culture with A. xylosoxidans) in our CF centre population and what is the prevalence 
of A. xylosoxidans colonisation (= at least 3 positive cultures during a period of 9 
months) in our CF centre population? 
Answer: The prevalence of at least one positive A. xylosoxidans culture in our CF centre 
population is 17.9% and the prevalence of A. xylosoxidans colonisation in our CF centre is 
5.3%. Colonisation or chronic infection was especially seen in older patients, with more 
pronounced lung damage. 
 
Question 13. What is the clinical impact of A. xylosoxidans colonisation? 
Answer: Over the study period A. xylosoxidans colonized patients needed more 
intravenous antibiotic treatment courses (19 versus 5, p < 0.001), nevertheless there was 
no significant difference in lung function decline over the study period  (FVC:  -6.25% ± 
12.34 versus - 5.62% ± 8.30, p = 0.77,  FEV1:   -5.62%± 8.30 versus  -1.87%± 11.58,  p < 
0.47). 
 
 
From all these results we conclude that the diversity of P. aeruginosa genotypes in the 
Belgian CF population is large, although cluster genotypes are present. For A. 
xylosoxidans the genetic diversity in the rehabilitation centre is limited. 
 
 Several of our findings point to the importance of patient-to-patient transmission : 
1. P. aeruginosa cluster strains are present in the Belgian population (although 
infection from a common environmental source can not be excluded). 
2. transmission of P. aeruginosa  during the study period in the rehabilitation centre of 
De Haan is confirmed, although the transmission is mostly transient. 
3. siblings almost always had the same P. aeruginosa genotype. 
4. in the national study patients with a shared P. aeruginosa  genotype had a 
significantly higher inter patient contact score.  
5.  A. xylosoxidans cluster strains are present in the rehabilitation centre population , 
moreover, all patients carrying  A. xylosoxidans shared at least one strain with 
others. We could even show that 2 patient pairs with the same A. xylosoxidans also 
shared the same P. aeruginosa genotype.  
 
Thus, this work in general supports the segregation measures for CF patients, so much 
debated in CF literature.  
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 IX. Perspectives for further research 
Derived from the experience we built up the last years in the domain of genotyping of these 
gram-negative organisms in CF, other research projects have been set up.  
 
A national multicentre study is almost completed, examining the possible home 
environmental origin of P. aeruginosa, when the germ is isolated for the first time from 
sputum of a formerly P.aeruginosa negative patient.  . 
The 7 Belgian CF-centres send sputum of 'newly' infected P.aeruginosa. patients between 
Jan. 2003 and Dec. 2005. The CF-nurses took cultures at the home of the patient (sinks, 
showers, swimming pools, nebulizers etc…). The environmental ánd patient isolates will be 
compared genotypically and the patients ‘newly acquired ‘ P. aeruginosa genotype will be 
compared to the ‘Belgian database’, to study whether patient-to-patient transmission occurred.  
 
Also another multi-centre study will be started soon, investigating the use of  molecular 
methods for early detection of Pseudomonas aeruginosa infection. 
Although early infection with P. aeruginosa is aggressively treated with increasing success 
there are currently no treatment schedules which enable eradication of  P. aeruginosa once 
colonisation is established. Therefore early treatment can significantly increase quality of life 
and life expectation.  
Early treatment, however, requires means for early detection of infection. 
In order to detect early infection by P. aeruginosa, regular sputum cultures, pharyngeal swabs 
or nasopharyngeal aspirates are carried out at all Belgian CF centres. At the moment of the 
first positive culture for P. aeruginosa one wonders for how long the micro-organism was 
already in the lungs of the patient. Therefore, since it is of utmost importance to start 
antimicrobial treatment as early as possible and as such enhance the possibility to eradicate P. 
145
 aeruginosa, more sensitive detection methods are warranted.  Thus, PCR-techniques on 
sputum, nasopharyngeal aspirate and broncho-alveolar lavage will be developed and 
compared with cultures. PCR positive/culture negative patients will be followed intensively 
and time to a positive regular culture will be evaluated. The PCR results will be correlated 
with a dosage of P. aeruginosa antibodies. 
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 Summary 
Pseudomonas aeruginosa is known to be the most important pathogen in CF, and is 
associated with increased morbidity and reduced life expectancy. Although we are convinced 
that peer contacts are psychologically beneficial for patients dealing with CF, we wanted to 
ensure that our patients did not experience more harm than benefit from these contacts, by 
patient-to-patient transmission of bacteria. Therefore, we set up 2 studies to evaluate the risk 
of patient-to patient transmission: a pilot study in the rehabilitation centre of De Haan (2001-
2002) and a national study, in collaboration of all 7 Belgian CF centres (2003-2004). From 
both studies we could derive that the majority of P. aeruginosa colonised patients carried a 
unique genotype, though small clusters of patients (ranging from 2 to 12 patients) with the 
same genotype could be described. During the study period in the rehabilitation centre, where 
patients stayed for at least 3 weeks, there were 3 patients for whom persistent cross-infection 
could be suspected. We considered this risk comparable with the risk of getting infected from 
the environment. Both studies showed that, in the individual patient, morphologically 
different looking colonies often had the same genotype. The national study revealed that most 
patients (80%) continue to carry the same strain, when genotyped one year later. For those 
who had a different genotype than the year before, no ‘new’ genotypes could be linked with 
the known centre genotypes of 2003, except for 1 patient, whose novel genotype appeared to 
be identical to a genotype recovered from his sibling in 2003. This made us draw the 
conclusion that the segregation policy in the CF centres seems to work! 
It also showed us, by means of a questionnaire score, that the patients carrying a 
‘cluster’genotype, had a significantly higher score for social contacts than those with a 
‘unique’ P. aeruginosa genotype. This led to the conclusion that the ‘cluster’genotypes are 
acquired from patient contacts in the past, which supports the need for segregation. These 
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 studies also showed that about 2/3 of the P. aeruginosa colonised patients carried only one 
genotype, about 1/3 2 genotypes and only a small minority 3 types. 
 
We also described probable patient-to-patient transmission of A. xylosoxidans in the 
rehabilitation centre population, with only four genotypes that were identified from 102 
isolates of 13 patients. These findings contradicted previous studies reporting that transmissibility of   
A. xylosoxidans is low! A. xylosoxidans is an emerging pathogen in older CF patients. 
Because litlle is known about the transmissibility and pathogenicty of the organism, the need 
for segregation A. xylosoxidans colonised patients remains unclear. 
Therefore we studied the prevalence of A. xylosoxidans in our CF population and the possible 
pathogenicity of this organism in a retrospective case control study. At the moment of the 
first positive culture we found significantly lower Bhalla-scores on HRCT scans of the lungs, 
lower Brasfield chest X-ray scores and lower FVC values. There was a significantly higher 
need for intravenous antibiotics for A. xylosoxidans colonized patients, but no more rapid 
decline in lung function. Therefore we hypothesized that A. xylosoxidans is a coloniser of 
more damaged lungs rather than a destructive infectious organism, however it is obvious that 
more, especially prospective, studies on the clinical relevance of  A. xylosoxidans infection or 
colonisation are needed.  
The low prevalence of A. xylosoxidans (and S. maltophilia) in individual centres warrants national 
or even international studies to draw statistically significant conclusions about the pathogenicity 
and need for treatment of these organisms. 
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 Samenvatting 
Pseudomonas aeruginosa is het belangrijkste pathogeen micro-organisme bij 
mucoviscidosepatiënten, en leidt tot verhoogde morbiditeit en verminderde 
levensverwachting. Niettegenstaande onze overtuiging dat contacten tussen patiënten 
onderling psychologisch voordelig kunnen zijn, wouden we er ons toch van vergewissen dat 
deze contacten niet meer kwaad dan goed deden, door mogelijks kruisinfectie. 
Daarom hebben we 2 studies opgezet om dit risico op kruisbesmetting te evalueren: een 
pilootstudie in het Zeepreventorium van De Haan (2001-2002) en een nationale studie, in 
samenwerking met de 7 Belgische CF-centra (2003-2004). 
Uit beide studies konden we concluderen dat de meerderheid van de patiënten een ‘uniek’ 
genotype van P. aeruginosa droegen, hoewel (eerder kleine) ‘clusters’ van patiënten (2-12 
patiënten) met hetzelfde genotype konden beschreven worden. 
Tijdens de studie in het revalidatiecentrum van De Haan, waar patiënten minimum 3 weken 
verbleven, kon voor 3 patiënten een persisterende kruisinfectie vermoed worden. We 
beschouwden dit risico vergelijkbaar met het risico om uit de omgeving besmet te worden. 
Beide studies toonden aan dat colonies van  P. aeruginosa, die er op de kweekplaat 
fenotypisch verschillend uitzagen, uiteindelijk vaak genotypisch gelijk waren. 
De nationale studie leerde ons dat patiënten meestal hetzelfde genotype droegen, één jaar 
later. Wanneer echter een ander genotype gevonden werd 1 jaar later, kon dit niet 
gecorreleerd worden aan gekende genotypes uit 2003, behalve bij 1 patiënt, van wie de broer 
dit genotype reeds droeg in 2003. Daaruit durfden we concluderen dat de 
segregatiemaatregelen in de centra wel degelijk hun werk doen. 
 Aan de hand van een vragenlijst die polste naar verschillende mogelijkheden van sociaal 
contact onder patiënten, konden we ook aantonen dat patiënten met een ‘cluster’type een 
hogere ‘contact score’ hadden dan de patiënten met een ‘uniek’ genotype. 
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 Dit leidde tot de conclusie dat de ‘clustergenotypes’ verworven werden via kruisinfecties in 
het verleden (vóór de segregatiemaatregelen van toepassing werden), wat ons steunde in onze 
overtuiging dat segregatie tussen P. aeruginosa-positieve en -negatieve patiënten een 
noodzaak is. 
Beide studies toonden ook aan dat ongeveer 2 derden van de gekoloniseerde patiënten slechts 
1 genotype ‘huisvesten’, ongeveer 1 derde 2 types en slechts een kleine minderheid 3 types. 
 
We beschreven ook mogelijke kruisinfectie van A. xylosoxidans, gezien tijdens de studie in 
het revalidatiecentrum van De Haan uit 102 isolaten van 13 patiënten (met co-colonisatie van 
P. aeruginosa) uiteindelijk maar 4 verschillende genotypes konden worden gevonden. Deze 
bevindingen spraken vroegere literatuurgegevens tegen, die stelden dat kruisinfectie met A. 
xylosoxidans weinig waarschijnlijk was.   
Er is echter nog maar weinig gekend over het ziekmakend vermogen en de transmissie van dit 
organisme, vandaar dat er geen standpunt bestaat over de nood van segregatie bij A. 
xylosoxidans gekoloniseerde patiënten. Daarom bestudeerden we de prevalentie van A. 
xylosoxidans in onze CF populatie en de pathogeniciteit in een retrospectieve ‘case control’ 
studie. Deze studie toonde aan dat op het moment van eerste positieve kweek, er reeds een 
significant lagere Bhalla-scores op longCt wordt gezien, evenals lagere Brasfield scores van 
de conventionele RX thorax en lagere FVC worden. 
Ook werd aangetoond dat de patiënten met A. xylosoxidans een hogere nood aan intraveneuze 
antibioticakuren hadden, doch géén snellere longfunctievermindering. Vandaar de hypothese 
dat A. xylosoxidans eerder een ‘colonisant’ is van sterk beschadigde longen ,  dan wel een 
echt ziekmakend organisme. Het is duidelijk dat er meer studies nodig zijn, en dan liefst 
prospectieve, om deze zaak op te helderen.  
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 Om de zorg voor de mucoviscidosepatiënten nog verder te verbeteren moeten er nationale, of 
nog beter, internationale studies opgezet worden, gezien individuele centra over een te klein 
aantal A. xylosoxidans (én S. maltophilia) gekoloniseerde patiënten beschikken om statistisch 
significante conclusies te trekken over de pathogeniciteit, de behandeling én eventuele 
preventiemaatregelen van deze kiemen. 
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vertrouwen en de autonomie in de uitbouw van onze kinderpneumologische dienst. 
 
Ook de Belgische Vereniging voor de Strijd tegen mucoviscidose mag in dit dankwoord niet 
ontbreken, omwille van de financiële steun aan de verschillende onderzoeksprojecten. 
 
Ook aan de medewerkers van de andere Belgische CF-centra én van het Zeepreventorium in 
De Haan ben ik dank verschuldigd voor de bereidwillige medewerking aan de multi-
centrische studie. 
 
Dank aan Dr. Hans Verstraelen voor de begeleiding bij het verwerken van statistische 
gegevens. 
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 Dit werk werd opgedragen aan het thuisfront: aan Jo, voor zijn voortdurende stimulatie door 
opmerkingen zoals “Is dat doctoraat nu nog niet af!?”, aan onze kinderen Arno, Zoë en Eva 
voor de aandacht die ze moesten missen door dit werk ‘van lange adem’ en aan mijn ouders, 
die mij alle kansen in het leven hebben gegeven en mij geleerd hebben “dat je moet werken, 
om er te geraken!” 
 
Last but not least heb ik dit werk ook opgedragen aan de mucoviscidosepatiënten. 
Dank voor de bereidwilligheid om steeds deel te nemen aan de onderzoeksprojecten. 
Weet dat ik jullie absoluut niet zie als ‘proefpersonen in een studie’, maar als mensen van 
vlees en bloed die het verdienen een correcte, wetenschappelijk gebaseerde en vooral een 
ménselijke behandeling te krijgen. Ik bewonder echt de moed en de levenskracht waarmee 
velen van jullie dagdagelijks omgaan met jullie ziekte. Jullie levenshouding houdt mij 
bescheiden en zorgt voor een groter relativeringsvermogen….dank!  
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